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Abstract 
Bovine viral diarrhea virus (BVDV) is an endemic pathogen in the U.S. cow herd.  The 
virus can cross the placental barrier and infect the unborn fetus.  If infection occurs between 45 – 
125 days of gestation, persistent infection (PI) in the unborn fetus is likely.  Upon parturition, the 
PI calf is a lifelong shedder of BVDV significantly elevating the risk of viral exposure to non-PI 
cattle.     
  Despite reports of significant production loss, many BVDV infections are subclinical 
and in some cases inconsequential.  Our data has highlighted various factors potentially causing 
disparity in clinical outcomes following BVDV exposure including: variation of BVDV serum 
concentration among PI cattle which may influence the quantity of virus shed into the 
environment, preexisting BVDV immune (i.e. antibody) status among non-PI cattle, and the 
degree of stress experienced by non-PI cattle all may influence the susceptibility of disease.  
Additionally, cattle transiently infected (TI) with BVDV may temporarily shed BVDV thereby 
offering another source of exposure to non-PI cattle. 
Programs focusing on BVDV control and prevention consist of diagnostic tests to 
identify PI cattle, BVDV vaccines to reduce fetal infection and increase herd immunity, and 
biosecurity programs intended to prevent BVDV exposure to the resident herd.  Survey work 
performed in Montana suggest that educating beef producers with regard to BVDV has 
significantly increased the implementation of these tools in order to reduce the risk of 
introducing BVDV to their resident herd.   
Despite the risk of production loss, the economic benefit of instituting whole-herd BVDV 
tests may vary due to herd prevalence.  By utilizing Monte Carlo simulation, the current BVDV 
herd prevalence within the U.S. does not economically justify a nationwide BVDV eradication 
campaign.  However, known BVDV positive herds and herds with an elevated likelihood (47%) 
of being BVDV positive displayed a positive economic outcome when whole-herd BVDV 
testing strategies were implemented across herd sizes of 50, 100, and 500 cows.  The value of 
testing various testing modalities was dependent upon herd prevalence and herd size.  These data 
suggest that veterinarians must critically evaluate the value of implementing whole herd testing 
protocols in U.S. beef herds
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Abstract 
Bovine viral diarrhea virus (BVDV) is an endemic pathogen in the U.S. cow herd.  The 
virus can cross the placental barrier and infect the unborn fetus.  If infection occurs between 45 – 
125 days of gestation, persistent infection (PI) in the unborn fetus is likely.  Upon parturition, the 
PI calf is a lifelong shedder of BVDV significantly elevating the risk of viral exposure to non-PI 
cattle.     
  Despite reports of significant production loss, many BVDV infections are subclinical 
and possibly inconsequential.  Our data has highlighted various factors potentially causing 
disparity in clinical outcomes following BVDV exposure including: variation of BVDV serum 
concentration among PI cattle which may influence the quantity of virus shed into the 
environment, preexisting BVDV immune (i.e. antibody) status among non-PI cattle, and the 
degree of stress experienced by non-PI cattle may all influence the susceptibility of disease.  
Additionally, cattle transiently infected (TI) with BVDV may temporarily shed BVDV thereby 
offering another source of exposure to non-PI cattle. 
Programs focusing on BVDV control and prevention consist of diagnostic tests to 
identify PI cattle, BVDV vaccines to reduce fetal infection and increase herd immunity, and 
biosecurity programs intended prevent BVDV exposure to the resident herd.  Survey work 
completed in Montana suggests that knowledge of BVDV among beef producers has 
significantly increased the implementation of these tools in order to reduce the risk of 
introducing BVDV to their resident herd.   
Despite the risk of production loss, the economic benefit of instituting whole-herd BVDV 
tests may vary due to herd prevalence.  By utilizing Monte Carlo simulation, the current BVDV 
herd prevalence among cow-calf herds within the U.S. does not economically justify a 
nationwide BVDV eradication campaign based upon whole-herd testing.  However, known 
BVDV positive herds and herds with an elevated likelihood (0.47) of being BVDV positive 
possessed a positive economic outcome when whole-herd BVDV testing strategies were 
implemented across herd sizes of 50, 100, and 500 cows.  The value of various testing modalities 
was dependent upon herd prevalence and herd size.  These data suggest that veterinarians must 
critically evaluate the value of implementing whole herd testing protocols in U.S. beef herds.
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Preface 
The body of work in the ensuing chapters provides a brief overview of the complexity of 
BVDV itself and the decisions to institute control and prevention strategies.  This intricacy is 
driven not by the inability to diagnose or prevent the disease but by the question of whether or 
not it is economically valid to do so.  Given prior data displaying the wide variation in clinical 
and economical outcomes, the honest answer to the question of economical justifiability of 
implementing diagnostic and control plans is “it depends”.  The ambiguity of this answer is 
frustrating to many (especially diagnosticians) but is the reality of biology and the world in 
which the practicing veterinarian resides.  Therefore, the economic effectiveness of a BVDV 
control plan solely depends upon the risk of introduction (i.e. prevalence of disease), the 
likelihood that BVDV will cause disease (i.e. pathogenicity) if infected, and the impact that 
disease may have on health and production.  The veterinary literature provides several different 
clinical and economic outcomes (spanning from economic devastation to inconsequential 
findings) when cattle are exposed to BVDV.  The obvious question that arises from these 
observations is what is the cause (or more likely “causes”) of this variation?  In our own work, 
we have observed this variability first-hand (Chapters 3 and 4), evaluated one potential source of 
variation (Chapter 2), assessed numerous management practices and their association with herd 
BVDV status (Chapter 5), and determined the economic feasibility of implementing a BVDV 
diagnostic testing protocol based upon the intended testing strategy, BVDV herd prevalence, and 
herd size (Chapter 6).  Given the findings in the following chapters, individual points of view 
regarding BVDV control (e.g. federal animal health regulators, diagnosticians, and private 
practitioners) will likely differ based upon clinical background and field experience with BVDV.  
Nonetheless, all things considered, decisions regarding BVDV control and prevention strategies 
must be made in accordance with what program (if any) is most economically effective and 
possesses the greatest likelihood of compliance at the farm level.  All in all, failing to evaluate all 
available data in regards to the economic justification of implementing a BVDV control strategy, 
veterinarians are at risk of committing a very costly mistake to the producer.
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CHAPTER 1 - The Effects of Bovine Viral Diarrhea 1 
Virus in Beef Production Systems 2 
Overview 3 
Upon first being described in 1946, bovine viral diarrhea virus (BVDV) has enthralled 4 
and perplexed the veterinary medical community worldwide.  The fascination with this pathogen 5 
is likely attributed to the biology and subsequent complexity of the virus, the potential to 6 
manifest in various clinical syndromes, and the uniqueness of the production of immunotolerant 7 
and persistently infected (PI) cattle which serve as an inapparent carrier and source of virus to 8 
healthy animals.   9 
Despite the negative clinical implications historically associated with BVDV, clinical 10 
outcomes can be highly variable.  Prior research and anecdotal reports suggest that BVDV can 11 
manifest as both a highly detrimental pathogen to any and all bovine production systems or be an 12 
inconsequential finding.1-13  These observations are intriguing and fuel continual debate 13 
regarding the proper avenues and the scale of monetary resources that should be directed towards 14 
prevention and control.  The objective of this chapter is to provide a broad overview of BVDV, 15 
provide examples of variation in clinical outcomes, describe the prevalence of certain 16 
management practices potentially associated with BVDV introduction, and address the need of 17 
assessing the economic variability in the implementation of current PI animal testing protocols.    18 
History and Background of BVDV 19 
The clinical effects of BVDV were first described as a case series during the 1946 20 
meeting of the New York State Veterinary Medical Association.1  At the time of that meeting, 21 
the disease had been observed in six dairy herds; however, the etiology of this novel syndrome 22 
had not yet been discovered.  The original clinical description indicated that this syndrome was 23 
primarily composed of severe gastro-enteritis with subsequent persistent diarrhea.1  Across all 24 
six herds, the risk of morbidity and mortality was observed to range from 33% – 88% and 4% – 25 
8%, respectively.  Additional clinical signs early in the course of disease included depression, 26 
anorexia, and mild diarrhea with a slightly elevated rectal temperature.  Within two days after the 27 
onset of diarrhea, affected cattle were observed to develop ulcerations on the muzzle, in the 28 
mouth, and in the nose.  Muco-purulent nasal discharge was evident while some diseased cattle 29 
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displayed a cough throughout the course of the disease process coupled with tachycardia and 1 
tachypnea.  Milk production was shown to be severely reduced and complete blood counts 2 
revealed moderate to severe leukopenia.  Following acute disease onset, abortions were observed 3 
in five of the six herds while some cows were noted as to have aborted without evidence of 4 
clinical disease.  Symptomatic treatment was provided which included antimicrobial therapy and 5 
blood transfusions.  However, the authors noted that all treatment modalities (including large 6 
doses of penicillin) did not appear to provide clinical benefit.1 7 
Experimentally, the authors observed that the disease was transmissible by fecal-oral 8 
exposure, by subcutaneously injecting naïve cattle with blood from infected individuals, and by 9 
oral exposure to splenic emulsion from diseased cattle (euthanized during the height of the 10 
disease process).1  Naïve heifers exposed to various inoculants were shown to develop a fever 11 
seven to nine days post-exposure lasting in duration of three to six days.  Diarrhea was observed 12 
to ensue soon thereafter lasting three to five days while severely compromising the hydration 13 
capability of the individual animal.  One to three days after the onset of diarrhea, oral ulceration 14 
was observed thereby worsening the current anorexia and dehydration status.  Ulcerations were 15 
noted throughout the oral cavity, naso-pharynx, larynx, and esophagus.  Lower intestinal lesions 16 
were present but less severe.  However, ulcerative lesions among cattle surviving the clinical 17 
episode were shown to rapidly dissipate.1   18 
A subsequent report indicated that a virus had been isolated from the previously 19 
mentioned cases and that the syndrome had been coined “viral diarrhea virus”.14  These early 20 
observations and experimental findings were soon followed by additional reports describing 21 
similar clinical signs, outcomes, and evidence of transmissibility among herds in the U.S., 22 
Canada, and Europe.10,12-19   23 
In summary, the cumulative body of research provided a large degree of evidence that a 24 
novel, highly infectious and economically destructive disease process was prevalent in the 25 
bovine population.  In addition, this clinical syndrome soon appeared to possess a worldwide 26 
prevalence. 27 
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 1 
The Role of BVDV in Bovine Reproduction 2 
Mature female beef cattle optimize their production by annually becoming pregnant, 3 
maintaining that pregnancy, and generating a live calf.  Therefore, infectious and noninfectious 4 
etiologies negatively influencing the efficiency of this reproductive process can reduce the 5 
economic viability of the production system.  The potential negative impact of BVDV on 6 
reproduction may be one of its most harmful (and economically devastating) characteristics.  7 
Early observations among BVDV researchers consistently associated reproductive wastage with 8 
the disease.1,11,12,20-23  However, these early reports of abortion outbreaks (supposedly linked with 9 
prior bouts of clinical and subclinical “viral diarrhea”) were merely circumspect as authors were 10 
unable to isolate BVDV from aborted fetuses.1,11,12,18-20,22  The theory that BVDV could indeed 11 
infect the unborn fetus was later reinforced by observing BVDV antibodies in fetal bovine serum 12 
harvested in slaughterhouses thereby suggesting that in utero exposure to BVDV had occurred.24   13 
Further association of BVDV with reproductive loss was observed upon isolation of a 14 
non-cytopathic (NCP) BVDV from two aborted fetuses.25  This finding was experimentally 15 
evaluated by Gratzek (1968) in which 12 fetuses (of different ages) were directly injected with 16 
BVDV while in utero.26  Abortions were observed in six of the pregnant cows while the 17 
remaining fetuses were shown to possess pre-colostral BVDV antibodies at birth.26  These 18 
findings were further applied in studies where the pregnant dam (not the fetus) was directly 19 
infected in order to externally validate the effects of BVDV on the unborn fetus.  These studies 20 
utilized mature cattle that were in the last trimester of pregnancy.  Although abortion failed to be 21 
observed, multiple calves displayed pre-colostral antibody titers to the same BVDV that infected 22 
the pregnant dams.21,27 23 
These observations and experimental findings suggested that numerous outcomes were 24 
possible upon BVDV fetal infection and may be attributed to the timeframe of gestation of when 25 
infection occurred.  Kendrick et al (1971) attempted to describe this variation by experimentally 26 
infecting pregnant cattle in all three trimesters of pregnancy.22  Among the BVDV antibody 27 
negative cows infected while in the first trimester of pregnancy (n=9), three calves aborted, one 28 
was mummified, one was still-born, one was full-term with partial alopecia, and three appeared 29 
normal.  Conversely, all cows in the second and third trimesters (n=14) delivered live healthy 30 
calves without evidence of abnormalities except for the presence of pre-colostral antibodies to 31 
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the virus.  Although the authors were unable to isolate BVDV from any of aborted, stillborn, or 1 
normal calves (a finding that still frustrates diagnosticians today), these findings suggested that 2 
BVDV could indeed cause reproductive failure but that the outcome depended on when the dam 3 
was infected during her pregnancy.  Dams infected early in pregnancy appeared to be at greater 4 
risk of pregnancy wastage compared to cattle in later stages of gestation.22  These findings and 5 
hypotheses were soon confirmed by Casaro et al 1971 who infected cows with BVDV at various 6 
stages of pregnancy (51 – 256 days).  These authors isolated BVDV in 23 of 26 fetuses and 7 
further displayed a trend of reduced clinical effects in older fetuses (second and third trimester) 8 
when compared to fetuses infected in the first trimester.23 9 
Ensuing studies described the pathogenesis of pregnancy wastage attributed to BVDV.  10 
Studies evaluating the outcome of BVDV on the female reproductive tract, infertility, and early 11 
embryonic death suggest that the effects of BVDV during the first trimester of pregnancy are 12 
vast and may be attributed to direct oocyte damage, oophoritis (encompassing a reduction in 13 
follicular development and hormone production), or salpingitis/metritis which may significantly 14 
impact the dam’s ability to maintain the preganancy.28-36  Other research also found that BVDV 15 
could induce abortion at any point of gestation.37-39 16 
Alternatively, in addition to infertility and pregnancy loss, BVDV has also been 17 
associated with numerous congenital defects when in utero infection occurs during the timeframe 18 
of 100 – 150 days of gestation.  This timeframe of infection appears to increase the probability of 19 
defects due to concurrent fetal organogenesis.  Most reported defects predominately involve the 20 
central nervous system; specifically cerebellar hypoplasia,27,40-43 microencephalopathy,44 21 
hydrocephalus,44 hydranencephaly,44 porencephaly,45 and hypomyelination.46  Ocular defects 22 
have also been commonly reported including cataracts,47,48 microopthalmia,41,42,49 retinal 23 
degeneration,41 and optic neuritis.47  Other ancillary reported defects include thymic 24 
hypoplasia,39 hypotrichosis and alopecia,22 mandibular brachygnathism,50 and growth 25 
retardation.39,51  Calves stricken with these abnormalities are severely handicapped at birth and 26 
frequently die soon thereafter or are subsequently euthanized.52 27 
In summary, the effects of BVDV on pregnancy have been shown to be driven by the 28 
timing of infection with regard to fetal age.  Previous research has observed that the bovine fetus 29 
and the status of the pregnancy are most susceptible to damage early in gestation.  The risk of 30 
negative clinical implications is reduced in the latter stages of pregnancy. 31 
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The Manifestation and Clinical Implications of Cattle Persistently Infected 1 
with BVDV 2 
In addition to variable reproductive outcomes attributed to BVDV, fetal infection 3 
occurring early in gestation may lead to offspring that are immunotolerant and persistently 4 
infected (PI) with the virus.  Persistent infections are attributed to fetal infection occurring prior 5 
to the development of a competent immune system by the fetus.  Therefore, upon maturation of 6 
the fetal immune system, the preexisting BVDV infection is observed to be a “self” antigen and 7 
therefore the immune system fails to clear the viral infection.  If the fetus survives gestation and 8 
is born alive, the calf is then a lifelong shedder of the virus thereby representing a highly 9 
infectious source of BVDV to herd and pen mates.  Due to this consistent source of virus, PI 10 
cattle serve as the reservoir of BVDV infection. 11 
The phenomenon of BVDV PI was first theorized by Kendrick (1970) who recommended 12 
that the concept of immunotolerance should be studied due to prior observations of cattle with 13 
mucosal disease (MD) being unable to produce antibodies to the BVDV of which it was 14 
infected.22  Ensuing research recognized PI cattle; however, the significance of this class of cattle 15 
(i.e. lifelong viral distributors) was not fully appreciated as research was relegated to the 16 
immunological and clinical outcomes of individual PI animals.53,54  The characterization of PI 17 
cattle as chronic shedders of BVDV was first observed in 1978 in a PI Holstein-Friesian bull.55  18 
The authors discovered the bull’s PI status at birth by the presence of BVDV in precolostral 19 
blood and synovial fluid samples.  Intermittent sample collection from the bull throughout the 20 
ensuing two and a half years displayed BVDV in multiple bodily fluids including blood (buffy 21 
coat), nasal discharge, lacrimal secretions, and semen.55  Immunocompetancy for other 22 
pathogens was observed in the PI bull due to the production of antibodies to parainfluenza type 3 23 
and bovine adenovirus despite failing to produce antibodies to BVDV throughout the study 24 
period.55  The pathogenicity of the recovered BVDV from the PI bull was then demonstrated by 25 
exposing two colostrum deprived neonatal Holstein calves to the isolated virus.  Both calves 26 
subsequently developed a fever and diarrhea lasting 5 – 7 days in duration and consequently 27 
produced antibodies one month after exposure to the BVDV of which they were inoculated.55   28 
Although Coria and McClurkin (1978) theorized that the production of PI cattle was 29 
attributed to the timeframe of fetal infection,55 McClurkin et al (1984) was the first to confirm 30 
this hypothesis.56  Five experiments were performed in which different sample populations of 31 
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pregnant cows were exposed to distinct strains of BVDV (4 non-cytopathic [NCP] and 1 1 
cytopathic [CP]) at varied stages of pregnancy.  Across the five experiments, BVDV was either 2 
injected directly into the amniotic fluid (via laparotomy) of the pregnant uterus or intravenously 3 
into the pregnant dam.  The range of gestation among the study subjects was 42 – 125 days.  The 4 
authors observed that the majority of fetuses exposed to NCP BVDV whom survived gestation 5 
were classified as PI to BVDV due to isolation of virus from the calves at parturition.  Fetuses 6 
born to dams infected with CP BVDV showed no evidence of PI but displayed precolostral 7 
BVDV antibodies to the CP virus.  All PI calves displayed immunocompetance to other antigens 8 
(bovine herpes virus, parainfluenza virus, and pasteurella multocida) by developing antibodies to 9 
all except the BVDV of which they were PI.56  The large majority of PI calves displayed normal 10 
disposition and subsequent growth.  One PI heifer lived to breeding age and was observed to 11 
give birth to a PI calf; however, the majority of PI calves died prior to the onset of puberty.  12 
These data suggested that BVDV infection of the fetus between days 42 – 125 of gestation can 13 
result in the production of PI calves.  Additionally, this study first suggested that PI cattle are at a 14 
high risk of dying prematurely; however, if females live until breeding age they may have a 15 
greater propensity to produce a PI calf.56   16 
Early classification of BVDV outbreaks distinctly discerned “viral diarrhea” and 17 
“mucosal disease” (MD) as two separate entities based upon clinical outcome, pathological 18 
description (antemortem and post-mortem), and histopathological differences in ulcerations of 19 
the alimentary tract.10,11,15-17,19,57  This theory was challenged by Thomson and Savan (1963) who 20 
experimentally induced “viral diarrhea” among neonatal calves resulting in clinical disease and 21 
virus isolation findings (i.e. cytopathic effects) typical of MD.58  Based on their findings, the 22 
authors suggested that the two syndromes were likely associated with the same pathogen and 23 
both clinical syndromes should be universally classified as “viral diarrhea”.  Further studies on 24 
PI cattle observed that only cattle displaying PI were shown to succumb to MD.54,59,60  Brownlie 25 
et al 1984 provided the first investigational report detailing a possible etiopathogenesis of MD by 26 
observing that both NCP and CP BVDV could be isolated from PI cattle dying of mucosal 27 
disease.61  Conversely, only NCP BVDV could be isolated from clinically normal PI cattle.  28 
Mucosal disease was then induced in two clinically normal PI calves by intra-nasal inoculation 29 
of a CP strain of BVDV.  Both PI calves displayed severe anorexia and diarrhea within three 30 
weeks of exposure.  Both calves were euthanized and post-mortem exams revealed lesions 31 
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consistent with mucosal disease.  The authors hypothesized that mucosal disease requires the 1 
animal to be PI (with NCP BVDV) and subsequently “superinfected” with a CP BVDV.61  This 2 
hypothesis was later confirmed by Bolin et al (1985).62 3 
The transmission of BVDV is optimized when susceptible cattle have direct contact with 4 
the virus.63  Potential sources of viral exposure include PI cattle,56,64-67 transiently infected (TI) 5 
cattle,36,68-72 wildlife,73-76 and various fomites.77-80  However, despite the various means of 6 
contracting BVDV, current beliefs indicate that exposure to PI cattle maximizes the risk of 7 
introducing or maintaining BVDV in the herd due to the concentration and consistency of viral 8 
shedding.  Cattle PI with BVDV shed the virus in all bodily secretions and excretions for the life 9 
of the animal.56,63-65  These data suggest that PI cattle are at risk of providing continual viral 10 
exposure to non-PI cattle thereby elevating the risk of morbidity, mortality, pregnancy wastage, 11 
and performance loss. 12 
  Despite the negative effects due to exposure to PI cattle, the prevalence of this 13 
subpopulation has consistently been shown to be low in both young stock and mature 14 
cattle,4,5,65,81-87  although clustering of PI cattle can be observed at the reproductive herd 15 
level.84,88  Persistently infected cattle have been observed to be at greater risk of overall 16 
morbidity/mortality when compared to non-PI cattle.89-91  In addition, poor growth rates have 17 
been previously documented among PI cattle.2,92 However, anecdotal reports suggest that many 18 
PI animals may appear clinically normally and indistinguishable from their non-PI counterparts.   19 
Variation in the economic impact of BVDV tends to parallel clinical outcomes.  20 
Numerous case reports and cohort studies describe the negative clinical effects and performance 21 
loss attributed to PI cattle in both cow-calf and feedlot production systems.2,4,8,9,93-99  Despite the 22 
reality that these clinical outcomes likely manifest in economic loss to the respective production 23 
system, there are limited peer-reviewed studies estimating the cost of BVDV in the cow-calf and 24 
feedlot sectors of the beef industry.  Waldner et al 2008 observed that cow-calf herds with 25 
evidence of BVDV exposure among the calves (based upon antibody titers) displayed 26 
significantly reduced weaning weights (-21.6 lbs; 95% CI, -7.7 to -35.4) compared to herds 27 
without evidence of exposure.8  Additionally, the risk of mortality was significantly greater in 28 
exposed herds compared to herds without evidence of BVDV; however, this effect was lost upon 29 
adjusting for the mortality of PI cattle.8  In the feedlot, Hessman et al 2009 observed that the cost 30 
of exposure to a PI calf among non-PI cattle housed in the same or adjacent pen ranged from 31 
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$41.84 – $93.52 per head; this finding was driven predominately by performance losses 1 
($88.26/hd) and fatality ($5.26/hd).9   2 
Despite the quantity of literature depicting negative clinical and economic effects 3 
attributed to BVDV, several authors have failed to observe health or performance loss among 4 
cattle exposed to PI calves.  O’Connor et al 2005 followed 5,041 calves (housed in 50 pens) from 5 
arrival to slaughter at a commercial Iowa feedlot.5  The authors observed that the risk of 6 
morbidity among pens containing PI cattle and pens not containing PI cattle were not statistically 7 
different (P>0.05).5  Similarly, other researchers observed no statistical differences in the risk of 8 
morbidity and mortality as well as performance differences among commercial feedlot pens with 9 
or without PI cattle.6,7   Elam et al 2008 observed no adverse effects (health, performance, and 10 
carcass quality) among pens of heifer calves exposed to PI cattle for both a short duration (60 11 
hours) or for the duration of the feeding period when compared to cattle not exposed to PI 12 
calves.100  Additionally, the presence of PI cattle either in the pen or in adjacent pens did not 13 
appear to affect feedlot or carcass performance.100 14 
The discovery of the ability of BVDV to persistently infect unborn fetuses was a major 15 
advancement in the realm of BVDV research by providing researchers and practicing 16 
veterinarians with a possible description of the viral reservoir.  However, ensuing observational 17 
studies revealed a vast degree of variation in the clinical and economical outcomes among cattle 18 
exposed to PI individuals.  Nonetheless, future control and programs would center on the 19 
identification and prevention of PI cattle. 20 
Genetic Variability of BVDV   21 
The initial 45 years of BVDV research focused on the pathogenesis of the virus, the 22 
discovery and clinical implications of PI cattle, and the institution of basic control programs 23 
based upon one viral genotype.  However, in the early 1990’s, new observations surfaced 24 
regardin a severe form of BVDV shown to manifest in a variety of novel clinical signs induced 25 
by thrombocytopenia including bloody diarrhea, epistaxis, petechial and ecchymotic 26 
hemorrhages, mucosal ulcerations, and injection site hemorrhages coupled with mortality risks as 27 
high as 10% – 20%.101-104  Further research indicated that these severe outbreaks were 28 
subsequently associated with a genetic variant subsequently categorized as BVDV type II.105,106 29 
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Subsequent studies have revealed that not only does genetic variation delineate genotypes 1 
(types I and II) but variation within genotypes (i.e. subtypes) have also been identified.107-109  In 2 
the U.S., prevalence studies have since observed that type I BVDV (specifically type Ib) is more 3 
prevalent in U.S feedlots than type II BVDV.108,110,111  However, the realization of genetic 4 
variation of BVDV complicated and refuted previous notions that the efficacy of vaccine 5 
programs were sufficient and that mucosal disease could be diagnosed based solely on clinical 6 
signs (as mucosal ulcers were displayed on non-PI cattle with type II BVDV).112  Like type I, 7 
type II BVDV was also observed to induce reproductive losses and produce PI cattle as a result 8 
of fetal infection.113  However, the clear distinction between type II and type I infection was type 9 
II BVDV’s ability to occasionally induce severe clinical disease and kill acutely infected cattle 10 
similar to the effect of type I in early reports.  Further research suggested that type II clinical 11 
infections displayed a higher degree of virulence and clinical illness of longer duration compared 12 
to current type I BVDV.114   13 
In summary, the discovery of genetic variation (both within and between genotypes) of 14 
BVDV appeared to explain some variation in clinical observations among cattle transiently 15 
infected with BVDV.  However, this added variation complicated previous control programs that 16 
focused on vaccinating solely against type I BVDV.  Future vaccine studies would focus on 17 
genotype cross protection and the need for type II BVDV (and multiple type I subtypes) to be 18 
included in commercial vaccine products. 19 
The Role of BVDV in the Bovine Respiratory Disease Complex 20 
The bovine respiratory disease (BRD) complex is the most prevalent disease in the 21 
feedlot sector of the U.S. beef industry with economic effects including costs of prevention, 22 
treatment costs, loss of feed performance and carcass quality, culling, and mortality.115-119  23 
Numerous pathogens have been shown to induce and increase severity of clinical BRD.  In the 24 
feedlot setting, diagnostic investigations have repeatedly isolated BVDV from lung tissue of 25 
cattle with ante-mortem history (clinical signs and antimicrobial treatment) and post-mortem 26 
pneumonic lesions consistent with BRD.120-122  However, the role of BVDV in the disease 27 
process has long been controversial and the mode of pathogenesis has not been entirely 28 
understood.123  Nonetheless, the majority of current evidence indicates that the virus can play a 29 
significant role in the disease process.   30 
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As described above, the direct effects of BVDV can be extensive and have been observed 1 
to affect all age groups and classes of cattle.  However, in addition to these disease syndromes, 2 
BVDV also possesses the ability to immunocompromise its host by a variety of methods.124-126  3 
The vital feature of immunosuppression (due to BVDV infection) is the magnitude of disease 4 
risk secondary to elevating the host’s susceptibility to opportunistic pathogens.  Indeed these 5 
immunosuppressive properties of the virus have been associated with concurrent disease 6 
processes.99,127-131  7 
Cattle experimentally infected with BVDV (via endoscopic inoculation into the lungs) 8 
showed clinical symptoms (albeit mild when compared to cattle infected with both BVDV and 9 
Mannheimia hemolytica) thereby indicating that BVDV can directly cause BRD.132,133  However, 10 
despite these findings, the majority of data suggests that the immunosuppressive characteristics 11 
of the virus (described above) which may increase the severity of clinical signs by potentiating 12 
infection with opportunistic pathogens is the main mode of action for BVDV associated 13 
BRD.129,131-134  14 
In summary, veterinarians have long observed a wide array of clinical syndromes 15 
associated with BVDV.  The earliest accounts of the disease describe a high prevalence of 16 
diarrhea and overall illness as well as reproductive consequences among adult 17 
animals.1,10,14,18,21,58,135  Further studies added to the multi-dimensional nature of the virus by 18 
identifying different biotypes (NCP and CP),25,136 the importance of those biotypes with regard to 19 
PI cattle production and mucosal disease,56,61,62 recognizing its ability to genetically mutate while 20 
displaying changes in virulence,104,106,137 observing that most infections are mild or 21 
subclinical,1,91 the ability of the virus to compromise the immune system of its host thereby 22 
increasing the risk of concurrent disease,99,125,126,128,129,132,138 and, finally, identifying its 23 
association with BRD.132,134  Indeed, the name “viral diarrhea virus” is not only redundant but is 24 
also a misnomer based on its numerous clinical manifestations as well as the modern rarity of 25 
recognizing diarrhea being directly associated with BVDV infection.  Despite these realizations, 26 
the variation in clinical outcome among different bovine populations is likely attributed to the 27 
potential genetic differences among BVDV strains, pre-existing immunity to BVDV, behavioral 28 
characteristics (i.e. the rate of contact) among populations housing infected cattle, and the level 29 
of viral exposure introduced to the population.104,139,140  30 
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Diagnosis and Control of BVDV 1 
As previously outlined, BVDV can manifest in numerous clinical syndromes varying 2 
significantly in outcome.  Veterinarians and producers are not only interested in the clinical 3 
effect of BVDV but also the impending economic cost to cow-calf and feedlot production 4 
systems.  The anticipated cost of this disease drives the implementation of control and prevention 5 
BVDV strategies.3,8,9,141   Unfortunately, a large amount of frustration and continued economic 6 
loss is typically realized when attempting to implement a control program by entrusting only one 7 
preventative strategy.142  Realistic expectations of BVDV control should begin by understanding 8 
a farm or ranch’s current production system including:  current BVDV status, risk of BVDV 9 
introduction, goals for herd production, and the most effective way of measuring 10 
improvements.142  Once these factors have been determined, the optimal BVDV control program 11 
can be designed and implemented.  Multiple tools are currently available to offset the potential 12 
negative effects of BVDV including use of diagnostic testing strategies, vaccine protocols, and 13 
biosecurity programs. 14 
 BVDV Diagnostic Tests  15 
Antemortem BVDV diagnosis is chiefly intended to identify PI cattle in order to 16 
eliminate the primary source of viral exposure to healthy herd and pen mates.  Early methods of 17 
detection for PI cattle entailed two positive virus isolation tests of blood, serum, or buffy coat 18 
performed at 2 – 4 week intervals.  Although highly specific for PI cattle, this method of 19 
identification is highly laborious, time intensive, and expensive.142,143  Subsequent testing 20 
strategies such as immunohistochemistry (IHC),65,144-147 antigen capture ELISA (ACE),65,145,148 21 
and polymerase chain reaction (PCR)83,149-151 have focused on exploiting the propensity of the 22 
BVDV antigen to be deposited in skin tissue among PI cattle.  These testing modalities have not 23 
only provided a cheaper and more rapid alternative to VI, but have exhibited consistent 24 
capability of distinguishing among PI and TI cattle.65,142,143,145,148,151,152  However, due to the low 25 
prevalence of PI cattle, it is recommended that a subsequent test be performed on initial test 26 
positive cattle (and interpreted in series) in order to maximize diagnostic specificity and positive 27 
predictive values.143,152,153 28 
Because of the propensity of PI cattle to die at a relatively young age, the majority of PI 29 
animals are harbored among young stock;3,8,88,91 therefore, a cow-calf whole-herd testing strategy 30 
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should begin by screening the calf population.  This should be followed by testing all herd bulls 1 
and open cows and ending with tests performed on the dams of test positive calves.143,152  In the 2 
cow-calf sector, previous studies have indicated that the herd BVDV prevalence among U.S. 3 
beef herds is less than 10%.3,8,154  However, the within herd prevalence of PI cattle among 4 
positive herds has been observed to be highly variable indicating that PI cattle tend to be 5 
clustered among cow-calf herds.2,3,8,154  Due to the low herd prevalence, the majority of U.S. 6 
cow-calf herds may not economically benefit from implementing a whole-herd testing regimen.  7 
Previous data indicate that veterinarians are not highly accurate in diagnosing herd BVDV status 8 
based solely on clinical history.3  Therefore, veterinarians should cautiously implement whole-9 
herd testing protocols unless previous diagnostics have indicated that BVDV is circulating in the 10 
herd.  Alternatively, negative herds may benefit from testing incoming replacement cattle and 11 
stocker cattle in order to reduce the risk of introducing BVDV to the herd.155-158 12 
Despite the propensity of BVDV to inflict economic loss, veterinarians must be cognizant 13 
of the cost to the producer when instituting PI testing programs.  Larson et al 2002 performed a 14 
10 year cow-calf profitability model that compared three herd BVDV scenarios:  1) beef herds 15 
with no PI calves, 2) herds with at least one PI calf displaying a negative impact on herd 16 
reproduction, and 3) herds with at least one PI calf displaying a negative impact on herd 17 
reproduction, pre-weaning morbidity, and pre-weaning mortality.141  Their results indicated that 18 
herd BVDV prevalence highly dictated the potential profitability of instituting a BVDV testing 19 
program.  These findings suggest that economic justification may not be present for the 20 
implementation of BVDV testing protocols in all herds.141  Alternatively, veterinarians should 21 
evaluate the individual clinical histories of respective farms in order to gauge the likelihood of 22 
the testing protocol to produce a positive economic return.3,141 23 
 BVDV Vaccination  24 
A sound BVDV control program at the cow-calf level should include the administration 25 
of proven vaccine products in order to reduce the risk of fetal infection and clinical disease.  26 
However, realistic expectations regarding the vaccine’s ability to prevent BVDV infection 27 
should be thoroughly discussed between the veterinarian and the producer; unfortunately, failure 28 
to understand the limitations of a vaccine program may lead to frustration among beef 29 
producers.142    30 
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Despite different attributes among BVDV vaccines (i.e. modified-live and killed 1 
vaccines), it is imperative that labeled directions be followed.  Veterinarians must be cognizant 2 
of the production system and thereby judiciously implement vaccines based on current 3 
management practices and vaccine history.  Strategically administering vaccines optimizes the 4 
potential of disease prevention.  In the cow herd, vaccines should be administered prior to 5 
breeding in order to reduce the risk of fertility complications, early embryonic death, fetal 6 
infection, pregnancy wastage (abortions, stillbirths), and congenital malformation.159-163  Beef 7 
calves destined for feedlot systems should ideally be vaccinated well in advance of entry (e.g. 8 
prior to weaning) due to the stress and potential disease associated with that age bracket of 9 
cattle.164-167   10 
In addition to knowledge of individual production systems, veterinarians must keep in 11 
mind the genetic variability inherent within the virus.  The BVDV vaccine of choice should 12 
provide cross-protection against multiple BVDV isolates.  Although prior studies have displayed 13 
that type I BVDV vaccines provide sufficient cross-protection against multiple type I subtypes as 14 
well as a type II challenge,168-171  type II BVDV has been observed to induce disease and fetal 15 
infection with subsequent PI calf production among cow-calf herds administered a BVDV 16 
vaccine containing only the type I genotype.172  Presently, multiple commercial vaccines (both 17 
MLV and killed) contain both BVDV genotypes and have displayed efficacy in preventing fetal 18 
infection and clinical disease.163,173,174  The high prevalence of BVDV type 1b in U.S. feedlots 19 
has highlighted the possible need of incorporating that subtype into commercial vaccine products 20 
(the majority of which include only type 1a as the representative of the type 1 genotype).66,108  21 
However, recent data illustrates the potential of commercial vaccines (without BVDV type 1b) to 22 
prevent fetal infection among previously vaccinated heifers exposed to BVDV type 1b.175   23 
In the cow-calf sector, veterinarians implement vaccine protocols to not only reduce 24 
clinical disease but to safeguard against fetal infection.  Presently, multiple commercial vaccines 25 
(both MLV and killed) contain both BVDV genotypes and have demonstrated efficacy in clinical 26 
trials by preventing fetal infection and clinical disease.163,173,174  However, veterinarians and 27 
producers should be wary of relying solely on vaccines in the prevention of fetal infection as 28 
multiple studies have shown that vaccines fail to provide 100% protection against disease 29 
challenge.113,159,161,163,175,176  Nonetheless, veterinarians should base their vaccine choice on 30 
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published literature, maximizing the genetic variation within the vaccine, prior experience, and 1 
the practicalities of each individual production system. 2 
 Biosecurity  3 
A sound biosecurity program is likely the most effective measure at either maintaining a 4 
negative BVDV status and/or reducing the risk of viral exposure to the resident herd.142,157,158  5 
Unfortunately, this component of BVDV prevention can be difficult to implement and maintain 6 
due to lack of producer awareness regarding the risk of disease introduction associated with 7 
current production practices, the lack of facilities to institute a biosecurity program, and a lack of 8 
appreciation for its importance.  Nonetheless, veterinarians must stress the significance of this 9 
component in order to supplement diagnostic testing and vaccination protocols to further reduce 10 
of the risk of introducing BVDV to the herd.  The implementation of a quality biosecurity 11 
program is typically accomplished by first identifying potential avenues for disease introduction, 12 
evaluating the necessity of those practices and potential alternatives, and managing them 13 
accordingly.142 14 
The introduction of BVDV into a previously negative cow herd is commonly attributed to 15 
the introduction of new cattle.142,157,158  Ideally, herd additions should be quarantined from the 16 
resident herd, screened for BVDV upon arrival, and maintained in an isolated location until test 17 
results are received and transient infections have likely cleared.142,155,157  The risk of importing an 18 
adult PI animal has shown to be very low;85-87 however, cattle acutely infected with BVDV can 19 
shed the virus making them potentially infectious to members of the resident herd.  The 20 
introduction of stocker cattle poses an additional risk due to an increase in the prevalence of PI 21 
cattle among stockers and the sheer number of individuals entering the herd.  Importation of 22 
pregnant cattle may increase the risk of BVDV introduction due to the unknown PI status of the 23 
unborn fetus.  Smith et al 2008 displayed that importation of either or both of these 24 
aforementioned classes of cattle greatly increased the likelihood of introducing BVDV to the 25 
resident herd.155  However, the risk associated with stocker cattle was reduced by testing all 26 
stocker calves for BVDV upon arrival and testing the offspring of imported pregnant cattle at 27 
parturition.155  Preventing fenceline contact and/or communal grazing between the stockers and 28 
the resident herd may sufficiently offset this risk without incurring the test cost.  Conversely, to 29 
mitigate the risk of the unborn fetus, incoming pregnant females should not only be quarantined 30 
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and confirmed BVDV negative but should be isolated from the resident herd until BVDV status 1 
of the calf is confirmed upon parturition.142,155 2 
In addition to the management practices described above, additional practices that 3 
potentially increase the risk of BVDV introduction include fenceline contact with neighboring 4 
herds,157,158 communal pasture sharing among herds,157,158 reintroduction of cattle to the resident 5 
herd after off-site activities (e.g. exhibition, breeding),142,157 procurement of bull semen from 6 
private distributors,71,177-179 and potential wildlife contact.73-76  Most of these activities (with the 7 
exception of wildlife contact) can either be strictly avoided (e.g. buying semen only from 8 
commercial vendors) or can be handled by implementing biosecurity protocols to these classes of 9 
cattle that parallel those described above for replacement animals. 10 
BVDV Risk Analysis 11 
The goal of adding risk analysis to the BVDV control program is to assist in the 12 
identification of the most cost-effective preventative program.156,180  In other words, risk analysis 13 
is implemented to identify potential disease risks, determine the probability of their occurrence, 14 
determine the cost of those respective disease risks if they were to occur, estimate the cost of 15 
disease prevention, and approximate the magnitude of risk mitigation attributed to the prevention 16 
program.156  Biologic processes inherently possess certain degrees of variation.  One form of risk 17 
analysis, stochastic modeling, allows the user to incorporate the variation thus providing a more 18 
realistic outcome (i.e. distribution) among production systems (when compared to deterministic 19 
models) thereby generating the information needed to make sound decisions.156,181 20 
In summary, optimal BVDV control programs consist of combining both the magnitude 21 
of risk reduction afforded by the disease control program with the cost of implementation.142  22 
Therefore, our goal as veterinarians is to ensure that BVDV control programs reduce the risk of 23 
an outbreak (or the magnitude if one should occur) but to also ensure that the program can be 24 
economically validated.  Therefore, optimal BVDV control programs consist of not only risk 25 
management tactics (e.g. diagnostic tests, vaccine protocols, and biosecurity programs) designed 26 
to reduce the probability of introducing BVDV to the resident cow herd but also institute the 27 
practice of risk analysis which provides the tools to help quantify the potential impact of a 28 
certain risk.181   29 
Conclusion 30 
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The history of BVDV is fraught with evidence of disease and production loss.  1 
Historically, BVDV has been associated with numerous clinical syndromes and possesses the 2 
ability to immunocompromise the host thereby leading to concurrent disease.  Fetal infection can 3 
cause of wide array of outcomes including pregnancy wastage and congenital malformation.  4 
Additionally, fetal infection occurring between days 42 – 125 of gestation has been shown to 5 
produce immunocompetant calves that are subsequently PI for life and thereby shed variable 6 
concentrations of BVDV into their environment.  Although the prevalence is low, PI cattle are 7 
thought to be the viral reservoir and must be identified and removed for optimal BVDV 8 
prevention.  A high degree of variability among clinical and performance outcomes has been 9 
displayed among cattle exposed to PI animals.  Therefore, a single recommendation for PI testing 10 
protocols, vaccine administration, and biosecurity practices may not always be in the best 11 
economic interest of the respective production system.  In the cow-calf sector, BVDV control 12 
and prevention is practiced at numerous levels including the identification of PI cattle present in 13 
the resident herd (diagnostic testing), reducing the risk of fetal infection and abortion 14 
(vaccination), and prevention of introducing BVDV to the resident herd (biosecurity).  Given the 15 
significant cost of these programs and the variability of disease magnitude, veterinarians have 16 
recognized that optimal BVDV control involves not only risk management practices but also risk 17 
analysis methods in order to identify the most cost-effective control programs.  An optimal 18 
BVDV control and preventative program would account for both the risk of acquiring BVDV 19 
with the cost of control and prevention. 20 
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 1 
CHAPTER 2 - Variation in Viremic Concentration 2 
among Cattle Persistently Infected with Bovine Viral 3 
Diarrhea Virus 4 
Introduction 5 
The potential of a non-cytopathic (NCP) bovine viral diarrhea virus (BVDV) to 6 
persistently infect (PI) the bovine fetus was first described by McClurkin et al (1984).56  Since 7 
that time, much work has been undertaken to fully understand the clinical, epidemiologic, and 8 
economic impact of the PI animal.3,64,91,143,155,182-185  Cattle PI with BVDV excrete the virus in all 9 
bodily secretions and excretions for the life of the animal.64,182-184  This characteristic maximizes 10 
the efficiency of viral distribution to non-PI cattle thereby making PI cattle the main reservoir of 11 
BVDV.3,56,91   Control programs focused on BVDV mitigation vary based upon current clinical 12 
scenario, PI prevalence, and BVDV risk avoidance preferences of the owner.143,155   In order to 13 
significantly reduce the risk of BVDV infection, PI cattle must be identified and removed from 14 
non-PI cattle; therefore, multiple diagnostic tests have been developed and validated to identify 15 
PI cattle.65,145,146,148-151,186,187  16 
Despite the number of reports incriminating PI cattle and BVDV as a major threat to the 17 
health and productivity of the bovine industry,4,8,9 multiple authors suggest that comprehensive 18 
PI testing is not a valid economical endeavor due to the low prevalence of PI cattle.141,155,188  In 19 
addition, other reports suggest that PI cattle may not be consistently relevant in the feedlot when 20 
comparing pens of cattle housing a PI(s) to pens without PI cattle.5,7,100  This discrepancy in the 21 
literature is perplexing, but may suggest that all PI cattle are not equally effective in transmitting 22 
BVDV.  Brock et al (1998) descriptively reported that the viremic concentration of BVDV 23 
appeared to change over a two-year time-frame in seven PI yearling cattle.183  Therefore, one 24 
hypothesis for varied health outcomes in cohorts of cattle following PI exposure may be 25 
variability in the amount of BVDV shed by PI cattle.  However, to our knowledge, there are no 26 
published reports of changes in viremia levels of PI cattle over time as determined from multiple 27 
serum samples taken at regular intervals.  The objectives of this study were two-fold.  The first 28 
objective was to determine if serum viral concentrations of BVDV differed among multiple PI 29 
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cattle.  The second objective was to determine if BVDV serum viral concentration of PI cattle 1 
differed significantly over time.  Three studies were designed to answer these questions. 2 
Materials and Methods 3 
All live animal studies were conducted and samples collected using protocols approved 4 
by the Kansas State University (KSU) Institutional Animal Care and Use committee. 5 
Study 1 6 
Study one was a cross-sectional study composed of 12 mixed breed beef calves averaging 7 
840 lbs (381 kg) and 21 mixed breed beef calves averaging 353 lbs (160 kg) housed at two 8 
different commercial feedlots within the state of Kansas.  All calves were maintained within 9 
open-air, dirt floor pens.  Upon entry to the respective feedlot, a presumptive diagnosis of BVDV 10 
PI was determined by antigen capture ELISA (ACE) of ear tissue.  These BVDV PI calves were 11 
subsequently isolated from the general feedlot population and housed together.  A second ACE 12 
was performed at least four weeks after initial testing to confirm PI status on the suspect cattle.  13 
On the day of confirmatory sample collection, one six milliliter (ml) whole blood sample was 14 
collected by jugular venipuncture in a sterile clot tube from each individual calf.  Within 24 15 
hours of sample collection, all samples were centrifuged at 3700 rpm for 10 minutes.  The serum 16 
was harvested into individual cryovials and stored at -176° F (-80° C) until virus isolation (VI) 17 
was performed.   18 
Study 2  19 
Six mixed-breed beef calves averaging 450 lbs (204 kg), presumptively diagnosed as PI 20 
with BVDV, were identified and managed by typical industry standards in a commercial Kansas 21 
feedlot.  These calves were initially diagnosed by one ACE test on ear biopsy specimens and 22 
subsequently removed from the general population and fed in an isolated pen for the duration of 23 
the feeding period.  Inclusion criteria for Study 2 consisted of two factors:  1) a positive follow-24 
up ACE performed at least four weeks after the first ACE test and 2) two positive virus isolation 25 
(VI) tests two to four weeks apart.  Sample collection was performed every seven days for one 26 
month by the feedlot’s consulting veterinarian.  Whole blood was collected by jugular 27 
venipuncture in sterile clot tubes (five mls) and EDTA tubes (four mls).  These specimens were 28 
mailed overnight to the Kansas State Veterinary Diagnostic Lab (KSVDL).  Plasma and serum 29 
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were harvested immediately following receipt of samples and stored at -176° F (-80° C) until VI 1 
was performed.   2 
Study 3  3 
 Four mixed-breed beef calves averaging 485 lbs (220 kg) were diagnosed as presumptive 4 
PI cattle by one ACE on skin biopsy. Confirmation of PI status following arrival to KSU for this 5 
study was achieved by the same inclusion criteria and diagnostic regimen as Study 2.  Calves 6 
were individually housed in outdoor pens measuring 20 square feet at a KSU animal resource 7 
facility.  A minimum of 12 feet (3.66 meters) was placed between each pen to avoid direct 8 
contact between calves and thereby limit potential cross-contamination between pens.185  Each 9 
individual pen was equipped with a small holding chute to secure the respective calf as well as 10 
individual feed and water sources.  Disposable sleeves, gloves, and boots were worn to avoid 11 
cross-contamination between PI calves and new apparel was used for each pen.  Five mls of 12 
blood were collected in red-top clot tubes and four mls of blood were collected in tubes 13 
containing EDTA by jugular venipuncture from each calf approximately every three days for 45 14 
days.  Serum and plasma were harvested immediately following sample collection and were 15 
stored at -176° F (-80° C) until VI was performed.      16 
Calves in study 3 were observed twice daily by a veterinarian to monitor for clinical signs 17 
of disease.  If symptoms warranted further investigation, animals were individually removed 18 
from their pens and walked to the processing facilities where a thorough physical examination 19 
was performed by the attending veterinarian.  Treatment of bovine respiratory disease (BRD) 20 
consisted of tulathromycina, enrofloxacinb, and oxytetracyclinec for the first, second, and third 21 
treatments, respectively.  Feed bunks were observed daily and the amount of feed distributed to 22 
each calf was allocated based on the consumption in the period since the last feeding.  Total 23 
amount (as fed) of daily feed delivery to each pen was recorded.  Water was available ad libitum 24 
throughout the trial.  25 
Virus Isolation 26 
Media for cell culture was produced by adding five mls of Penicillin-Streptomycin, two 27 
mls of Ciprofloxacin, five mls of Amphotericin B, 20 mls of L-glutamine and 70 mls of fetal 28 
bovine serum to one liter (L) of EMEM.  This mixture was inverted several times and set aside.  29 
Embryonic bovine lung (EBL) cells were washed with 12 mls of PBS prior to the addition of 30 
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four mls of Trypsin.  The flask was then incubated for 5-15 minutes.  The EBL cells were then 1 
resuspended in the cell culture media composed above.  The volume of media was determined by 2 
the number of plates needed (approximately 10mls/plate).  One hundred micro-liters (µls) of the 3 
media/EBL cell mixture were added to each well in 96 well micro-titer plates.  The plates were 4 
then incubated for two to six hours.  Six ten-fold serial dilutions in quadruplicate were performed 5 
for each sample in four ml plastic tubes.  A volume of 1.8 mls of media/EBL cell mixture was 6 
added to each tube.  Two hundred µls of the first sample (serum) was added to the first tube and 7 
vortexed.  Two hundred µls from the first tube was then removed and added to the second tube 8 
and vortexed.  This process continued until all six dilutions had been created.  One hundred µls 9 
of each respective sample/dilution were then added to the respective well in each plate.  The 10 
plates were then incubated for 48 hours.  The media in each plate was then discarded and the 11 
remaining cells were washed with FA-PBS.  An 80% acetone solution was then poured into each 12 
well and was allowed to sit for 10 minutes.  Upon discarding the acetone, the plates were 13 
allowed to dry at room temperature.  Fifty µls of anti-BVDV conjugate was added to each well 14 
and allowed to incubate for one hour.  The conjugate was then discarded and the plate washed 15 
with FA-PBS.  Fifty µls of 50% glycerol were added to each well.  The cell-culture infectious 16 
dose (CCID-50) was calculated by a previously described method.189 17 
Statistics 18 
The individual calf was the unit for all analyses.  Descriptive statistics were generated 19 
using a commercial software packaged.   Confirmation of homogeneity among the variance of the 20 
fixed effects was performed by general linear modelse.  Differences in BVDV serum 21 
concentrations among groups (Study 1), individual calves (Studies 2 and 3), and over the time 22 
(Studies 2 and 3) were evaluated by general linear mixed modelsf.  A first-order autocorrelation 23 
structure was used to account for the lack of independence among subsequent samples from the 24 
same animal (Studies 2 and 3).  All CCID-50 values were transformed to log10 outcomes to 25 
facilitate the normalization of data.  An alpha level of 0.10 was used for all analyses. 26 
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 1 
Results 2 
Study 1  3 
All 33 calves from both locations were confirmed to be PI based on the aforementioned 4 
inclusion criteria.  A statistical difference was not observed between serum BVDV 5 
concentrations (CCID-50) of cattle from the two locations.  The distribution of serum BVDV 6 
concentrations ranged from 101.75 to 104.5 among calves (Figure 4.1).   7 
Study 2 8 
All six calves in this study were confirmed to be PI by the inclusion criteria.  Serum 9 
BVDV concentrations across the sample population ranged from 101.75 to 103.75 throughout the 10 
time period of the study (Figure 4.2).  In this study population, one calf (#6600) exhibited 11 
significantly lower serum BVDV concentrations throughout the study compared to the other five; 12 
however, no significant differences were detected among the other five calves.  No differences 13 
were observed in serum BVDV concentration across weekly measures in this study.   14 
Study 3 15 
Of the four calves composing this study, one calf was found to be transiently infected 16 
with BVDV while the other three calves were confirmed to be PI based on the aforementioned 17 
inclusion criteria.  One PI calf succumbed to mucosal disease, confirmed by the KSVDL, shortly 18 
after the initiation of the study; therefore, data from this calf were not included in the analysis.  19 
Among the sample population, the distribution of raw CCID-50 values over the 45 day collection 20 
period was 102 to 104 virus particles per ml of serum.  Within individual calves, serum viral 21 
concentrations over time were observed to fluctuate from 101.75 to 104 during the study 22 
timeframe.  Significant differences were detected in BVDV viremia levels between individual 23 
calves (P=0.03) and over time (P=0.10).  Figure 4.3 depicts the raw BVDV serum concentration 24 
of both calves at each collection time point.  The model-adjusted serum BVDV concentration 25 
estimates were observed to significantly differ at adjacent sample collection time points of days 1 26 
and 3, 35 and 38, and 38 and 41.  27 
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 1 
Discussion 2 
Our results suggest that the BVDV serum concentrations in PI cattle have a relatively 3 
large distribution (Study 1), differ among PI cattle (Studies 2 and 3), and may change over time 4 
(Study 3).  Previous reports have descriptively illustrated that BVDV serum concentration ranges 5 
among PI cattle190 and may change over time183; however, to our knowledge, the present study is 6 
the first to quantitatively assess both factors.  The variability in BVDV serum concentration 7 
among PIs and over time identified in this study may help explain reported variability in 8 
population responses following exposure to PI cattle.4,5,7-9,100   9 
The methods implemented in this study for determining BVDV serum concentration have 10 
been well documented.65,183,191-193  Descriptively, the ranges in serum BVDV concentrations 11 
among PI cattle from our studies are similar to a previous study which reported a distribution of 12 
serum BVDV concentrations of 102 to 104 among 12 PI calves at one time point.65  Conversely, 13 
other studies have reported smaller distributions in serum viral concentrations; however, they 14 
tend to overlap those reported in the present study.  Bolin et al (1985) reported serum BVDV 15 
concentrations ranging from 104 – 105.8  virus particles per ml among nine two-year old mixed 16 
breed PI steers prior to receiving a modified-live vaccine.191  Patel et al (2002) observed serum 17 
titers of BVDV among four neonatal PI calves ranging from 102.2 – 102.5 soon after birth.68  18 
Although large ranges have been described, we are unaware of published data documenting 19 
statistical differences in BVDV serum concentration among PI individuals and over time.  20 
In both studies 2 and 3, we were able to identify significant differences in BVDV serum 21 
concentration among individual PI calves.  One cause of these differences could be the presence 22 
and concentration of maternal antibodies to the homologous strain of BVDV still circulating at 23 
the time of sample collection.  Palfi et al (1993) reported a lack of detectable virus in 11 newborn 24 
PI calves until six to eight weeks of age when BVDV maternal antibodies were observed to 25 
dissipate.194  Likewise, Brock et al (1998) observed a lack of serum BVDV in three of four 26 
neonatal PI calves until approximately 42 days of age when maternal BVDV antibodies 27 
waned.183  The level of maternal antibodies may influence serum BVDV concentrations, and 28 
although the PI calves in the present study were likely much older than the animals in these two 29 
reports, varied antibody levels may have played a role in our findings.   30 
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Another possible source of variation in serum BVDV concentrations may be attributed to 1 
spontaneous production of antibodies within the PI individual to the homologous strain of 2 
BVDV.  Brock et al (1998) described the first account of developing virus neutralizing 3 
antibodies to the homologous strain of BVDV, within a three year old PI steer, thereby 4 
preventing the isolation of BVDV in serum by VI over an 18 month period of time.183  5 
Additionally, Grooms et al (2001) observed transmission of BVDV between an eight-year-old PI 6 
cow housed with a non-PI steer in which BVDV could not be identified in the PI cow’s serum 7 
(but was present in buffy coat and nasal swab specimens).82  Despite these reports, PI cattle 8 
lacking detectable levels of serum BVDV due to homologous antibody production likely 9 
represents a small proportion of the PI population.  Further research is needed to determine why 10 
variation exists among serum BVDV concentrations of PI cattle. 11 
In addition to serum BVDV concentration disparities among individual PI cattle, our data 12 
also suggest that serum BVDV concentrations significantly fluctuate over time (Study 3).  Our 13 
findings agree with previous work that described an average decline in serum BVDV 14 
concentration of one log10 among five of seven adult PI animals, over a two year period.183  15 
Similar results were reported by Fulton et al (2009) describing a variation of one to two log10 16 
changes in serum BVDV concentration in several PI calves during an 11 month study.190   17 
The cause of the observed differences in serum BVDV concentrations over time are 18 
currently unknown, but are likely associated with a number of factors.  One potential explanation 19 
for fluctuation in serum virus concentrations may be various forms of stress, which have been 20 
shown to be detrimental in both animal and human viral infections.  Stress attributed to 21 
hyperthermic conditions and transportation has been associated with the recrudescence of herpes 22 
viruses in both the human and bovine species.195,196  Additionally, the stress of actively being 23 
restrained has been observed to increase the distribution of Theiler’s disease in humans. 197    All 24 
cattle included in the present study were restrained by standard industry processing facilities in 25 
order for sample collection to proceed.  Despite these data, the role of stress and environmental 26 
conditions in the variation of serum BVDV concentration among PI cattle is currently unknown.  27 
More work is needed to determine what factors may influence the variation in serum BVDV 28 
concentration over time among PI cattle. 29 
Despite the differences in serum BVDV concentrations among PI calves, these findings 30 
may not necessarily predict the viral load that non-PI cattle may encounter when exposed to a PI 31 
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individual.  Prior studies suggest that serum BVDV concentrations approximate viral levels in 1 
nasal secretions, urine, feces, and uterine secretions.64,65  However, Fulton et al (2009) observed 2 
that BVDV concentrations in nasal swabs were greater (102.55 – 103.50 differences in some cases) 3 
than serum BVDV concentrations and BVDV could be isolated from individual nasal swabs 4 
even when respective serum BVDV levels were undetectable by VI.190  Further research is 5 
necessary to determine if serum BVDV concentration is associated with the level of virus shed 6 
into the environment.   7 
  8 
 9 
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 1 
Sources and Manufacturers 2 
a.  Draxxin®, Pfizer Animal Health, Kalamzoo, MI 3 
b.  Nuflor®, Intervet/Schering Plough Animal Health, DeSoto, KS 4 
c. Biomycin 200®, Boehringer Ingelheim, Saint Joseph, MO  5 
d.  Microsoft Excel®, 2003, Redmond, WA 6 
e.  PROC GLM, SAS Institute, Cary, NC 7 
f.  PROC Mixed, SAS Institute, Cary, NC 8 
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 1 
Figure 2.1:  Distribution of BVDV serum concentrations at one point in time among 33 PI 2 
animals composing Study 1. 3 
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Figure 2.2:  Individual serum BVDV concentrations among PI calves (n=6) in Study 2 1 
measured weekly by VI for four weeks.  Note that calf # 4979 is missing data in Week 1. 2 
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Figure 2.3:  Individual serum BVDV concentration for two PI calves at each sample 1 
collection time point across a 45 day study period. 2 
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CHAPTER 3 - Evaluation of health and performance 1 
outcomes in stocker calves following the administration 2 
of a commercial vaccine containing a bovine viral 3 
diarrhea virus contaminant 4 
Introduction 5 
The strategic administration of commercial vaccines to cattle of all ages is a standard 6 
practice of general preventative veterinary medicine in the United States.  These products are 7 
composed of killed or attenuated organisms intended to improve the health and production of 8 
cattle.185,188,198  Vaccine purity is a constant concern due to the potential contamination of 9 
adventitious viruses, particularly virulent bovine viral diarrhea virus (BVDV).198,199  In the 10 
United States, BVDV is the most common contaminant of cell cultures used in the production of 11 
viral vaccines.200  The primary source of BVDV contamination is attributed to the utilization of 12 
fetal bovine serum (FBS) in viral vaccine production.201  Previous data reports the prevalence of 13 
BVDV infected FBS to range from 10% to 87% of tested one-liter lots.202-206   14 
During the summer of 2008, Schering Plough Animal Health (SPAH) confirmed that 15 
specific serials of two commercial vaccine linesa,b were contaminated with an extraneous type II 16 
NCP BVDV.  Two Kansas State University (KSU) beef cattle animal health studies employed 17 
one of the aforementioned vaccinesa (confirmed contaminated serial numbers) without 18 
knowledge of the BVDV contaminant.  The Fall 2007 study was originally conducted to evaluate 19 
metaphylactic protocols207 and incidence of BVDV transient infections in 293 beef feeder calves.  20 
The objective of the Spring 2008 trial was to observe 22 cattle post-vaccination to evaluate the 21 
potential of PCR to identify the BVDV fraction of the vaccine.  Both studies collected health, 22 
performance data, and blood samples from all cattle at numerous time-points.   23 
A retrospective cohort study was performed on stock-piled serum samples and data to 24 
analyze health and performance outcomes given the knowledge that the MLV vaccine contained 25 
an extraneous BVDV.  The objectives of this study were to evaluate the risk of contaminant 26 
BVDV viremia after vaccination, the duration of contaminant BVDV viremia, the association of 27 
pre-exposure BVDV serologic status and BVDV viremia, and potential associations of the 28 
contaminant BVDV viremia with health and feed performance in beef calves.   29 
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Materials and Methods 1 
Samples from two independent research trials were used to conduct the retrospective 2 
analysis.  The details of each trial are provided in addition to testing procedures conducted 3 
specifically for the current analyses.  All animals in both trials were handled in accordance with 4 
protocols approved by the Kansas State University Animal Care and Use Committee. 5 
Fall 2007 Trial 6 
Two-hundred ninety three mixed-breed beef bulls and steers of weaning age were 7 
procured in the southeastern United States and arrived to the KSU Beef Stocker Unit in three 8 
loads.  The facility housing the cattle is an all-in-all-out system thereby reducing the risk of 9 
extraneous sources of microbial exposure.  Upon arrival, cattle were individually weighed, 10 
identified (i.e. numbered ear tag), and gender (bull or steer) was determined.  Cattle were 11 
blocked by weight and gonadal status and randomly assigned to one of eight pens for each 12 
truckload by a computer generated random number systemc.  The first pen in each string was 13 
assigned to metaphylaxis treatment A or B by a coin flip.  Subsequent pens received alternating 14 
treatments. 15 
Twenty four hours after arrival, each calf received a two milliliter (mL) commercial 16 
MLV 4-way viral respiratory vaccinea, a two mL 7-way clostridial vaccined, injectable 17 
ivermectine, and one of two metaphylaxis treatments (A: tilmicosinf at 10mg/kg by subcutaneous 18 
(SC) injection, B: tulathromycing  at 2.5mg/kg by SC injection) and bulls were surgically 19 
castrated as described in a previous report.207   Two blood samples consisting of four mLs in 20 
EDTA tubesh and five mLs in clot tubesi were collected from each calf at arrival.  In addition, a 21 
1.5 squared centimeter (cm2) ear biopsy was collected from each calf by a standard ear notching 22 
device.j  Calves were readministered the same MLV respiratory vaccinea and 7-way clostridial 23 
vaccined 10 days after arrival.  Blood was again collected from all calves at revaccination in the 24 
same fashion as at arrival.  All products were administered per label directions.  Twice daily, 25 
cattle were fed a total mixed ration consisting of prairie hay, alfalfa, wet gluten feed, and cracked 26 
corn.  Feed bunks were observed once daily and the amount of feed distributed to each pen was 27 
based on the bunk score from that day.  Automatic watering systems were present in each pen 28 
and water was available ad libitum throughout the trial.   29 
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Each pen was observed twice daily by trained personnel to identify individual animals 1 
displaying clinical signs of disease.  A 72 hour post-metaphylactic treatment moratorium was 2 
observed for all cattle.  The case definition for cattle experiencing bovine respiratory disease 3 
(BRD) included observance of clinical signs and a rectal temperature of ≥ 40°C (104°F).  Cattle 4 
meeting the treatment criteria were treated with enrofloxacink (7.5-12.5mg/kg, SC), florfenicoll 5 
(40mg/kg, SC), and oxytetracyclinem (20mg/kg, SC) for the first, second, and third treatments, 6 
respectively.  In addition, blood samples were collected from all calves treated for BRD.  Calves 7 
designated with chronic respiratory disease (cattle meeting the BRD case definition after three 8 
treatments) were removed from their respective pen and placed in a pen housing other calves 9 
experiencing chronic BRD.  Gross post-mortem examinations were performed on all dead calves 10 
at the Kansas State Veterinary Diagnostic Laboratory (KSVDL).  At the conclusion of the 11 
feeding phase, cattle were weighed individually on the day they left the facility.   12 
Within 1 hour following blood collection, plasma and serum were harvested from each 13 
respective blood sample.  Blood (serum) and ear biopsy samples collected at arrival were tested 14 
for BVDV by real-time reverse-transcriptase polymerase chain reaction (PCR)n and antigen 15 
capture ELISA (ACE)o, respectively, on the day of arrival.  Plasma and serum collected from 16 
samples obtained at revaccination and from each calf treated for BRD was stored at -80°C.  All 17 
samples were analyzed for BVDV by PCR at the end of the study period.   18 
Spring 2008 Trial 19 
Twenty two mixed breed beef steers of weaning age were procured at a local livestock 20 
market (within 60 miles) and transported to Manhattan, KS.  All calves were housed in a single 21 
pen (2,090 m2) and isolated from other cattle throughout the duration of the study.  Calves were 22 
randomly assigned to receive either a MLV 4-way respiratory vaccinea (n=16) or sterile salinep 23 
(n=6) based on results from a random number generatorc.   24 
Two hours after arrival, each calf received its predetermined treatment (MLV vaccine or 25 
sterile saline), a two mL multivalent clostridial vaccineq, and injectable doramectinr.  All 26 
products were administered per label directions.  In addition, blood and ear biopsy specimens 27 
from each calf were collected in the same manner as calves in the Fall 2007 study.  Blood 28 
samples also were collected from all individuals in both treatment groups on days 7, 14, and 21 29 
post-vaccination.  Within 1 hour following sample collection, serum and plasma were harvested 30 
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from each respective whole blood sample and stored at -80°C until the end of the study period.  1 
Serum samples and ear biopsies were subsequently tested for BVDV by PCRn and ACEo, 2 
respectively.   3 
Each pen was observed twice daily by a veterinarian to identify sick cattle.  Calves 4 
exhibiting clinical signs of BRD were further evaluated by a complete physical examination.  5 
Cattle registering rectal temperatures ≥ 40° C (104° F) were treated with tulathromycing (2.5 6 
mg/kg SC), florfenicoll (40mg/kg, SC), and oxytetracyclinem (20mg/kg, SC) for the first, second, 7 
and third treatments, respectively.  At the conclusion of the study, all cattle left the facility on the 8 
same day. 9 
Serology 10 
Serum neutralization assays for type 1 and type 2 BVDV were performed on serum from 11 
both studies at the KSVDL by a previously described method.208  Antibody titers were quantified 12 
on arrival serum samples from cattle in the Fall 2007 trial and on multiple samples (arrival, day 13 
7, day 14, day 21) from cattle in the Spring 2008 study.  A titer ≥1:4 was classified antibody-14 
positive to BVDV throughout the data analysis.66  Four classifications of type 1 and type 2 15 
serology results were implemented:  cattle without antibody titers to both BVDV genotypes, 16 
cattle positive for type 1 antibodies but not type 2, cattle positive for type 2 antibodies but not 17 
type 1, and cattle antibody-positive to both genotypes. 18 
Real-Time Polymerase Chain Reaction 19 
Individual serum samples were pooled (up to 10) to create a volume of 200 micro-liters 20 
(µl).  Viral RNA was subsequently extracted using a commercial methods for PCR per the 21 
manufacturer’s recommendations.  Utilizing a commercial PCR kitn, five µl of the extracted viral 22 
RNA was added to 15 µl of master mix to comprise a total volume of 20 µl.  The PCR was 23 
performed by a commercial systemy as follows: reverse transcription at 45°C for 30 minutes, 24 
denaturation at 95° C for 2 minutes, 45 cycles of denaturation at 95°C for 30 seconds, and 25 
annealing/extension at 55°C for 60 seconds.  The BVDV specific amplification is detected by 26 
FAM (6-carboxyfluorescein) fluorescence.  To identify false negative results by inhibited PCR, 27 
the above mentioned kit contains an internal control in primer-probe-mix that is detected by VIC 28 
(2,7- dimethoxy-4,5-dichloro-6-carboxy-fluorescein) fluorescence.  Only when the internal 29 
control was positive and the PCR was non-inhibitory were its results were included in this study.  30 
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Positive and negative controls from the kit were included in each PCR.  At the end of each cycle, 1 
FAM fluorescence was measured and the cycle threshold (CT) was determined as the cycle 2 
number at which the increase in fluorescence is exponential.  When any of the pools were tested 3 
positive by PCR, each blood sample in those pools was extracted individually for PCR as 4 
described above. 5 
In the Spring study, three PCR tests were performed on every sample at each time point 6 
and results were interpreted in parallel; therefore, a sample was considered positive when at least 7 
one result out of three was positive.  A negative classification required negative results on all 8 
three PCR tests.    9 
RNA Sequencing 10 
Serum samples determined to be BVDV positive by PCRn were then tested by a genetic 11 
sequence method to further confirm the presence of the virus.  Individual serum samples were 12 
subjected to a PCR plus a melt curve analysis.u  The primers used (forward primer BVD-2F: 5’-13 
CATGCCCTTAGTAGGAC-3’, reverse primer 384: 5’-CCATGTGCCATGTACAG-3’) were 14 
modified from a previous report.209   These primers amplify a 283 bp fragment from both type 1 15 
and type 2 BVDV in the 5’ UTR region of the BVDV genome.  Samples with a melt curve at 16 
approximately 84°C were diluted 10-fold, and 1 µl of such diluted amplicons were used as 17 
templates for a regular PCR re-amplification to enrich the amplicon concentration, and to remove 18 
the SYBR Green dye that may interfere with sequencing reactions.  The resulting products were 19 
purified using a commercial purification kitv and outsourcedw for sequencing from both ends.  20 
Each pair of sequences was assembled into a 283 bp contig and compared with known type 1 and 21 
type 2 BVDV sequences to confirm the respective genotypes. 22 
Statistical Analysis 23 
The individual calf was the experimental unit throughout the data analysis.  General 24 
linear models were used to estimate the least square means of continuous outcomes for 25 
significant effects from the Fall 2007 study.x  Repeated measures (on pen and lot) were 26 
accounted for in all models, and the effects of metaphylaxis treatment and gender (both with 2 27 
levels) were forced into all models.  Logistic regression was employed to analyze proportional 28 
outcomes.y  Random effects of calf identification number, pen, and lot were accounted for in the 29 
analysis.  For the Fall 2007 trial, we measured the association between BVDV antibody titers at 30 
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arrival on the subsequent BVDV viremic status at revaccination, morbidity risk, mortality risk, 1 
and feed performance.  In addition, we evaluated potential associations between BVDV viremia 2 
at revaccination and morbidity risk, mortality risk, and feed performance.  For the Spring 2008 3 
study, we estimated the risk of viremia based on treatment group (vaccinate or control) and day 4 
of sample collection.  A subset of the data consisting of vaccinated calves in the Spring 2008 trial 5 
that were rt-PCR and sequence positive on day 7 (n=13) was created to evaluate  the probability 6 
of clearing the virus by day 21 post-vaccination and potential associations between arrival 7 
BVDV titers and subsequent duration of BVDV viremia.   8 
Results 9 
Fall 2007 Trial 10 
One hundred eighty bulls and one hundred thirteen steers averaging 218 kilograms (kg) 11 
were included in the three loads of calves comprising the Fall 2007 trial.  Cattle were at the 12 
growing facility for 43 (load one) or 41 days (loads two and three).  All arrival ACE (ear biopsy) 13 
and PCR tests (plasma) were negative for BVDV.  At arrival, 15.1% (n=44) of the calves were 14 
sero-negative to both BVDV genotypes, 34.2% (n=100) were sero-positive to BVDV type one 15 
but not type two, 3.4% (n=10) were sero-positive to type two but not type one, and 47.3% 16 
(n=138) were sero-positive to both genotypes.  17 
The overall morbidity risk, retreatment risk, and mortality risk for the trial was 51% 18 
(149/293), 48% (71/149), 9.5% (28/293), respectively.  One calf died the day of arrival (Load 3) 19 
but prior to vaccine administration.  The BVDV status of this calf was not determined.  In 20 
addition to gross necropsy, a diagnostic workup consisting of fluorescent antibody, virus 21 
isolation, and bacteriology tests were performed on 24 of the 28 dead calves.  Of these 24 calves, 22 
BVDV was isolated in 12 individuals from various tissues.   23 
At revaccination, 28.8% (81/281) of the remaining population were PCR positive for 24 
BVDV.  No statistical differences (P=0.7) were detected in the percentage of BVDV positive 25 
cattle among pens within the facility. Cattle found to be viremic with BVDV at revaccination 26 
(Day 10 post-vaccination) were at a higher risk of being treated for BRD, death, and treated 27 
significantly earlier in the feeding phase compared to non-viremic cattle (Table 2.1).  The overall 28 
average daily gain (ADG) of viremic cattle was significantly less compared to non-viremic cattle 29 
(Table 2.1).  Cattle viremic with BVDV at the first BRD treatment were observed to be at greater 30 
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risk (P<0.05) of being retreated for BRD (0.54; 95% Confidence Interval [95% CI], 0.39 – 0.67) 1 
compared to non-viremic cattle (0.34; 95% CI, 0.23 – 0.47) at first BRD treatment.  However, no 2 
association (P>0.05) was observed with regard to the risk of mortality at the first BRD treatment 3 
among viremic (0.14; 95% CI, 0.08 – 0.24) and non-viremic (0.15; 95% CI, 0.09 –0.25) cattle.   4 
The BVDV antibody status at arrival tended to be associated with BVDV status by PCR 5 
at revaccination (P=0.08).  The probability of testing positive to BVDV on day 10 by PCR for 6 
each BVDV antibody category is shown in Table 2.2.  However, no significant associations were 7 
detected between arrival antibody status for BVDV and morbidity or mortality risk, the number 8 
of days on feed prior to first treatment for BRD, or overall ADG. 9 
Spring Trial 2008 10 
Twenty two mixed-breed beef steers averaging 193 kg were enrolled in the Spring 2008 11 
study.  All arrival ACE (ear biopsies) and PCR tests (serum) were negative for BVDV.  At 12 
arrival, 43.8% (7/16) and 33.3% (2/6) of the vaccinated and control cattle, respectively, 13 
possessed antibodies (≥ 1:4) to both BVDV genotypes.  In the vaccinated animals, 81% (13/16) 14 
were PCR positive for BVDV seven days after vaccination, while 63% (10/16) were PCR 15 
positive on days 14 and 21, post-vaccination.  In non-vaccinated cattle, 17% (1/6) were PCR 16 
positive on days seven and 14 post-vaccination, while 50% (3/6) were PCR positive 21 days, 17 
post-vaccination. Throughout the entire 21 day study, 87.5% (14/16) of the vaccinates and 50% 18 
(3/6) of the control calves became PCR BVDV positive at least one time post-vaccination.  A 19 
morbidity risk of 4.5% (1/22) for bovine respiratory disease (BRD) was observed during the trial.  20 
No death loss was observed and ADG was not measured in this study. 21 
Sequencing of RNA confirmed that the positive PCR tests resulted from the contaminant 22 
BVDV originally identified by KSU during the Fall 2007 study.  A discrepancy between positive 23 
PCR and negative genetic sequence results from individual calves were observed on day 7 (n=1), 24 
day 14 (n=1), and day 21 (n=8).  In addition, four calves on day 21 had positive PCR results but 25 
inconclusive sequence data.  The remaining PCR and RNA sequence outcomes were identical.   26 
The model-adjusted probability of testing PCR positive throughout the study tended 27 
(p=0.06) to be higher in vaccinates (0.70; CI, 0.46 – 0.86) compared to non-vaccinated controls 28 
(0.26; CI, 0.06 – 0.67).  Likewise, the probability of testing BVDV positive by RNA sequencing 29 
was significantly different between vaccinates (0.41; CI, 0.21 – 0.64) and controls (0.024; CI, 30 
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0.002 – 0.23).  Across both treatment groups, the probability of testing positive to BVDV by 1 
RNA sequencing during the study was significantly different (Table 2.3).   2 
The probability of individual calves developing antibodies to BVDV types 1 and 2 over 3 
time in both treatment groups significantly increased throughout the course of the study (Table 4 
2.4).  No statistical differences were observed in the risk of developing BVDV antibody titers 5 
between days 0 and seven and days 14 and 21, post-vaccination (Table 2.4).  The risk of 6 
becoming antibody positive to BVDV type 1 did not differ between treatment groups.  However, 7 
vaccinated calves tended (p=0.08) to have a higher probability of becoming BVDV type two 8 
antibody positive compared to non-vaccinated calves throughout the study.   9 
A subset of the data was created to evaluate the potential association between arrival 10 
BVDV antibody status and the risk of clearing the BVDV infection by day 21, post-vaccination.  11 
These data included only vaccinated calves that became PCR positive and sequence positive for 12 
BVDV on day seven after vaccination (n=13).  Cattle antibody positive at arrival to both BVDV 13 
genotypes (4/13) tended (p=0.07) to possess a higher probability of being BVDV negative (0.75; 14 
CI, 0.19 – 0.97) on day 21 relative to antibody negative cattle (9/13) (0.11; CI, 0.01 – 0.56) 15 
based upon PCR results.  However, based upon genetic sequence data, no differences were 16 
observed between sero-status when comparing the risk of clearing the BVDV infection by day 17 
21. 18 
Discussion 19 
This retrospective analysis illustrates that administration of vaccine contaminated with 20 
BVDV was associated with calves testing PCR and sequence positive for BVDV (Spring 2008) 21 
and the subsequent viremia was associated with negative health and performance outcomes (Fall 22 
2007).  During these studies, we were unaware that the MLV vaccine administered to cattle was 23 
contaminated with a NCP type II BVDV.  Therefore, the observations of high morbidity and 24 
mortality risks, extensive BVDV viremia post-vaccination, and isolation of BVDV in dead cattle 25 
were not easily explained given the biosecurity of the cattle facility and the negative BVDV 26 
status of all cattle at arrival in both studies.  However, subsequent knowledge of the extraneous 27 
BVDV isolate contained in the vaccine provided the opportunity to retrospectively evaluate 28 
potential associations between the contaminated vaccine and the outcomes witnessed in both 29 
studies.   30 
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Prior reports investigating the administration of BVDV contaminated vaccine to cattle 1 
suggest that health and performance effects may vary.  Barkema et al (2001) described multiple 2 
episodes of type two BVDV infection following administration of a BVDV contaminated bovine 3 
herpesvirus 1 (BHV-1) vaccine in the Netherlands.210  Morbidity risk on five affected farms was 4 
observed to be greater than 70% while another farm was free of clinical illness.210  Likewise, 5 
Falcone et al (2003) described a NCP type two BVDV isolate, recovered from BHV-1 vaccine, 6 
which was inoculated into four three-month old calves.211  Three of the calves, sero-negative to 7 
BVDV at the time of inoculation, developed disease four to six days post-inoculation, and the 8 
BVDV isolated from these calves revealed 100% homology with the isolate recovered from the 9 
vaccine.211   10 
Despite administration of the contaminated vaccine to cattle in both studies, cumulative 11 
incidence risks for morbidity and mortality among cattle comprising the Fall 2007 trial (51% and 12 
9.5%, respectively) was relatively high compared to the Spring 2008 study in which virtually no 13 
adverse health effects were observed.  Potential explanations of disparity in disease risk between 14 
trials include differences in procurement (e.g. location, distance traveled, health history), 15 
management of cattle, and season of arrival to the research facility.   Cattle from the Spring 2008 16 
trial were obtained through a local livestock auction market (located approximately 60 miles 17 
north of Manhattan, KS) and were on feed for 21 days compared to 42 days for calves in the Fall 18 
2007 study.  Conversely, cattle composing the Fall 2007 trial originated in the southeastern 19 
sector of the United States, were assembled through multiple auction markets, and were 20 
transported from Tennessee to Kansas.  Only 22 head comprised the Spring 2008 study 21 
compared to 293 in the Fall 2007 trial, potentially minimizing the extent of commingling 22 
occurring among cattle from different origins.  The sample population from the Fall 2007 study 23 
was potentially subjected to a greater degree of stress, a higher level of microbial exposure, and a 24 
greater compromise of overall immunity compared to the Spring 2008 cattle.  Therefore, despite 25 
the fact that the same BVDV isolate was administered to both cattle populations, procurement 26 
and management disparities may have contributed to the dissimilarities observed in health 27 
parameters between the two studies.   28 
In the Fall 2007 trial, BVDV was not observed in cattle upon arrival; however, a 29 
moderate percentage of calves (28.8%) were subsequently BVDV PCR positive at revaccination.  30 
Given that commingling did not occur among cattle from different loads, a lack of difference 31 
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among the percentage of BVDV-positive cattle at revaccination across all pens suggests that 1 
there were not differential exposures among loads or pens.   However, given that the population 2 
was negative for BVDV at arrival and the strict biosecurity of the facility prevented random 3 
sources of exposure, the presence of BVDV at revaccination was likely induced by the 4 
administration of the vaccine to all calves at arrival.  The subsequent viremia at revaccination 5 
(day 10) was associated with negative health and performance outcomes.  This is in agreement 6 
with other authors who observed that the presence of viremia in cattle inoculated with BVDV 7 
was associated with elevated adverse health effects.171,212,213   8 
Despite the associations between BVDV viremia on day 10 post-vaccination and health 9 
outcomes in the Fall 2007 trial, it should be stressed that there was no negative controls in this 10 
study.  Therefore, this data cannot provide an estimate of the direct effect of vaccine 11 
administration on health and performance.  Although these findings illustrate an association 12 
between BVDV viremia at revaccination (day 10) and negative health and performance 13 
outcomes, they do not necessarily indicate causality.   14 
Surprisingly, the presence of BVDV antibody titers at arrival did not significantly impact 15 
health or performance outcomes in either study.  This is in contrast with a previous study that 16 
reported cattle with BVDV titers at arrival were associated with decreased odds of being treated 17 
for BRD;214  however, the cattle in that study were presumably not exposed to BVDV in the 18 
manner witnessed in the present study.   In the Fall 2007 study, BVDV antibody status at arrival 19 
tended to be associated with BVDV viremia on day 10.  Previous studies report that calves 20 
vaccinated with a type I BVDV MLV vaccine and subsequently infected with a type II BVDV 21 
isolate were protected from viremia and clinical disease.170,171  The present scenario is unique as 22 
cattle in both studies were administered the vaccine and the BVDV challenge at the same time 23 
thereby eliminating the opportunity for cattle to adequately respond to the vaccine prior to 24 
BVDV infection.    25 
The BVDV PCR results cannot be directly compared between the Fall 2007 and Spring 26 
2008 studies.  The same PCR test method was utilized in both trials; however, three tests were 27 
performed in parallel in the Spring 2008 study compared to only one test (at day 10) in the Fall 28 
2007 trial.  Therefore, a positive BVDV diagnosis was classified by at least one of three positive 29 
PCR tests in the Spring 2008 trial.  The integration of parallel interpretation likely increased the 30 
diagnostic sensitivity of detecting BVDV viremic calves in the Spring 2008 trial as compared to 31 
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the Fall 2007 study, but may have resulted in a reduction of diagnostic specficity.215  This 1 
method of interpretation was employed for the retrospective analysis in the Spring 2008 study 2 
due to the inclusion of serial sample collection over time and confirmed genetic sequence 3 
homology between BVDV isolated from cattle and the vaccine contaminant.  Maximizing the 4 
diagnostic sensitivity of the test increases apparent prevalence of viremic cattle at each 5 
respective time point.  This information is practical as it provides a potential “worst case 6 
scenario” of the prevalence of cattle at risk of shedding the BVDV contaminant post-vaccination.  7 
Conversely, the Fall 2007 trial did not provide sequential points of testing and sample quality 8 
was not sufficient to allow adequate interpretation of genetic sequencing results. Therefore, it is 9 
possible that the prevalence for BVDV viremia at revaccination and at the first BRD treatment is 10 
underestimated in the Fall 2007 trial. 11 
Vaccinated cattle in the Spring 2008 study tended to be at greater risk for viremia at any 12 
point during the study compared to non-vaccinated penmates.  However, 50% of the non-13 
vaccinated calves became viremic with the extraneous BVDV at least once during the study.  14 
This suggests that vaccinated cattle were shedding the BVDV contaminant to non-vaccinated 15 
cattle housed in the same pen.  The onset of horizontal transmission appears to be somewhat 16 
rapid as a control calf was PCR positive to BVDV by day seven, post-vaccination.  No additional 17 
samples were collected between days zero (arrival) and seven; therefore, an exact time lapse 18 
between shedding of vaccinated cattle and detectable viremia in negative controls cannot be 19 
determined.  These findings are similar to Fulton et al (2005) who studied the rate of BVDV 20 
transmission in 10 pens of healthy calves.66  In that study, one PI calf was housed with non-PI 21 
cattle in each pen for the duration of the study (35 days).66  Non-PI calves became viremic 22 
between days seven and 21, post-exposure.66  In our study, PI cattle were not present; however, a 23 
unique class of transiently infected (TI) cattle was produced due to the administration of the 24 
same extraneous BVDV isolate, at approximately the same time.  25 
No statistical differences were observed in the probability of testing positive for BVDV 26 
on each day of sample collection for the PCR test in the Spring 2008 study.  Conversely, 27 
vaccinated cattle displayed an increasing probability of being positive for BVDV on any of the 28 
three testing days based on genetic sequencing.  These data are likely attributed to differences in 29 
diagnostic sensitivity between the two tests and suggest that the viral load circulating in the pen 30 
was declining at this point in time.  The extraneous NCP type II BVDV was still present on day 31 
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21, post-vaccination, as diagnosed by PCR (n=13) and confirmed with genetic sequencing (n=1).  1 
However, we cannot be certain of the duration of infection or the probability of new infections 2 
arising since samples were not collected at later time points.  Therefore, regardless of testing 3 
method, our results suggest that cattle administered the contaminated vaccine are potentially 4 
viremic (and potentially infectious) for at least three weeks post-vaccination.  One limitation of 5 
these data is the length of time cattle were monitored in the spring 2008 study.  However, the 6 
study was designed based on the assumption that all cattle would have been non-viremic by 21 7 
days.  Other authors have reported BVDV vaccine viremia durations significantly shorter than 21 8 
days.160,193,216-218   9 
Conclusion 10 
Cattle administered MLV vaccine contaminated with a NCP type II BVDV isolate 11 
developed a transient viremia still present in one of 16 calves 21 days post-vaccination.  BVDV 12 
viremia 10 days post-vaccination, as diagnosed by PCR and presumably attributed to the BVDV 13 
contaminant, was a risk factor for BRD morbidity, BRD retreatment, mortality, and reduced 14 
weight gain.  Positive antibody titers for BVDV at arrival did not significantly affect 15 
performance of cattle vaccinated with the contaminated vaccine.  Additionally, the viral 16 
contaminant was observed to have been shed from vaccinated cattle to unvaccinated controls 17 
housed in the same pen.  Variation in health outcomes was witnessed across both studies. 18 
 19 
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Table 3.1:  Model-adjusted1 means and 95% confidence intervals for health measures 1 
(morbidity, repull, mortality, and days on feed (DOF) at first pull) and average daily gain 2 
(ADG) by BVDV status (by PCR) at revaccination for the Fall 2007 study. 3 
Revaccination 
BVDV Status 
Morbidity 
(%) 
Repull 
(%) 
Mortality 
(%) 
ADG 
(lbs) 
DOF at 1st Pull
(days) 
Positive 72.3 
(60.7 – 80.6)a 
69.8 
(55.7 – 81)a 
14.5 
(8 – 24.9)a 
1.7 
(1.5 – 1.9)a
8.5 
(7.1 – 9.9)a 
Negative 42.8 
(35.5 – 50.6)b 
20.7 
(12.8 – 31.7)b
2.9 
(1.3 – 6.4)b
2.5 
(2.4 – 2.7)b
10 
(8.8 – 11.3)b 
 4 
 a, bMeans in columns with different superscripts are significantly different (P<0.05) 5 
1 From mixed models accounting for viremia status at revaccination and arrival metaphylactic 6 
treatment as fixed effects.  Only the results of the effect of interest (risk of viremia) are reported. 7 
 8 
 9 
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Table 3.2:  Model-adjusted probability and 95% confidence intervals measuring the risk of 1 
individual cattle testing positive for BVDV on day 10 based on BVDV antibody status1 at 2 
arrival. 3 
BVDV Antibody Category Probability of being BVDV 
Positive on Day 10 by PCR 
95% Confidence Interval 
No BVDV antibody titers to 
either genotype 
0.53a 0.30 – 0.74 
BVDV antibody titers to 
type II, not type I 
0.54a 0.12 – 0.91 
BVDV antibody titers to 
type I, not type II 
0.50a 0.34 – 0.65 
BVDV antibody titers to 
both genotypes 
0.28b 0.17 – 0.42 
a, bMeans in columns with different superscripts are significantly different (P<0.05) 4 
1Based on least squared means and 95% confidence intervals from mixed models accounting for 5 
BVDV antibody status at arrival and metaphylactic treatment as fixed effects.  Only the results of 6 
the effect of interest (risk of BVDV viremia) are reported. 7 
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Table 3.3:  Risk1 and 95% confidence intervals for testing positive for BVDV by genetic 1 
sequence on days 7, 14, and 21, post-vaccination of cattle in Spring 2008 study (n=22). 2 
 Day 7 Day 14 Day 21 
Risk of positive PCR  0.48 
(0.20 – 0.78)a
0.36 
(0.14 – 0.67)a
0.56 
(0.32 – 0.78)a 
Risk of positive genetic sequence  0.39 
(0.13 – 0.72)a
0.22 
(0.06 – 0.56)a
0.01 
(0.001 – 0.13)b 
a, bMeans in rows with different superscripts are significantly different (P<0.05) 3 
1Based on least squared means and 95% confidence intervals from mixed models accounting for 4 
viremia status and treatment group at each day of sample collection.  Only the results of the 5 
effect of interest (risk of viremia) are reported. 6 
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Table 3.4:  Risk1and 95% confidence intervals for developing titers to BVDV genotypes 1 1 
and 2 on days 7, 14, and 21, post-vaccination of cattle in Spring 2008 study (n=22). 2 
 Day 0 Day 7 Day 14 Day 21 
BVDV type 1 (%) 0.30 
(0.08- 0.69)a 
0.38 
(0.11 – 0.76)a 
0.93 
(0.68 – 0.99)b 
0.96 
(0.75 – 0.99)b 
BVDV type 2 (%) 0.14 
(0.02 – 0.59)a 
0.14 
(0.02 – 0.59)a 
0.85 
(0.38 – 0.98)b 
0.96 
(0.67 – 0.99)b 
 3 
a, bMeans in rows with different superscripts are significantly different (P<0.05) 4 
1Based on least squared means and 95% confidence intervals from mixed models accounting for 5 
a titer status and treatment group at each day of sample collection.  Only the results of the effect 6 
of interest (risk of a positive titer) are reported.7 
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CHAPTER 4 - Evidence of viral transmission and nasal 
shedding among beef calves exposed to a calf persistently 
infected with bovine viral diarrhea virus 
Introduction 
Bovine viral diarrhea virus (BVDV) possesses world-wide prevalence and is a significant 
source of production loss in beef and dairy production systems.1-9  The viral reservoir is believed 
to be cattle persistently infected (PI) with BVDV which are lifelong shedders of virus thereby 
increasing the efficiency of viral transmission compared to transiently infected (TI) cattle.2-4,10  
Cattle PI with BVDV have previously been observed to possess serum viremias of 104 – 106 cell 
culture infectious dose50 (CCID-50)/ml.2,3,11 Serum BVDV levels also have been observed to 
approximate the viral concentrations in nasal secretions, urine, feces, and uterine secretions.2,12  
Primary BVDV prevention and control strategies are targeted toward increasing population 
immunity through vaccination or decreasing pathogen exposure by removing PI cattle and 
prohibiting their entry into the herd.13  Consequently, several diagnostic testing strategies,14-16 
and vaccination programs,17-19 and biosecurity protocols7,20,21 have been suggested to minimize 
the impact of BVDV.  
The onset, duration, and clinical effects among antibody-negative non-PI cattle when 
experimentally (intranasal or intramuscular inoculation) or naturally infected (by means of PI 
exposure) with BVDV have been studied.22-26  These findings suggest that BVDV antibody-
negative cattle transiently infected (TI) with BVDV are observed to be viremic (buffy coat and 
serum) between days 3-15 post-exposure,23,24 display widespread viral distribution to organ 
systems,23 may shed virus in nasal secretions,26 and display variable clinical outcomes.22,24   
Despite the knowledge gained from the aforementioned research, few studies have 
implemented models utilizing PI cattle as the mode of infection among clusters of non-PI cattle 
possessing diverse levels of BVDV antibody titers typical of cattle in commercial production 
operations.27-32    Determination of the time necessary for a non-PI calf to develop BVDV 
infection post-exposure to a PI calf is important as this may influence design of control 
programs.  The duration of the transient infection and the capability of these TI animals to shed 
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BVDV may also influence the magnitude of detrimental health impacts of BVDV in the 
population.   
A TI diagnosis has traditionally been performed by virus isolation (VI) on serum or buffy 
coat.  However, VI on buffy coat has been observed to provide more accurate results when 
compared to serum and is currently regarded as the recommended gold standard for BVDV 
diagnosis.10,27,28  Despite these recommendations, the logistical aspects of capturing the buffy 
coat fraction from a whole blood specimen may preclude practicing veterinarians from collecting 
buffy coat from field samples.  Serum provides the practitioners with a more convenient and 
practical alternative to buffy coat. 
The objectives of this study were two-fold:  1) to describe the frequency and time to onset 
of viral transmission between a PI calf and a non-PI study population in a production setting 
based on serum VI, and 2) to characterize the transient BVDV infection in the non-PI study 
population based on duration of positive serum viremic status and potential for shedding the 
virus in nasal secretions. A greater understanding of viral transmission in a beef cattle production 
setting facilitates knowledge-based modifications to current BVDV preventative and control 
programs.  
Materials and Methods 
All animals were handled in accordance with a protocol approved by the Kansas State 
University Animal Care and Use Committee.  The two studies were performed by introducing a 
known PI calf into a confirmed BVDV antigen-negative population of cattle.  The exposure 
period in each study lasted 21 days and multiple samples were collected throughout the studies. 
In study one, twelve mixed-breed beef steer calves, averaging 184.2 kg, were procured 
through a livestock auction market in northeast Kansas.  The health history of all calves was 
unknown at the time of purchase.  Fifteen days prior to PI calf introduction (day -15), all calves 
were delivered to a Kansas State University (KSU) facility consisting of an open-air dirt-floor 
pen with a total area of 544 m2 (5859 ft2).  Twenty-four hours after arrival (day -14), all calves 
received a two milliliter (mL) multi-valent clostridial vaccinea, an injectable dewormerb, and a 
topical insecticidec.  Additionally, a standard triangular ear biopsy, measuring approximately one 
cm2, was collected by a commercial ear notch deviced.  Blood was collected in one six mL red 
top clot tube and one four mL EDTA tube from each individual by jugular venipuncture.  A 
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second blood sample collected in the same manner was attained on day -4.  In study two, 15 
mixed breed beef bull calves were procured through the same industry channels and housed in 
the same pen as calves in study one.   On day -16, all bulls were surgically dehorned and 
castrated by standard industry approved methods and received a two mL multi-valent clostridial 
vaccinea, an injectable dewormerb, and a topical insecticidec.  Additionally, a standard ear notch 
biopsy, measuring approximately one cm2, was collected by a commercial ear notch deviced.  
Blood was collected in the same manner as in study one.  A second blood sample was collected 
on day -6.  In both studies, the inclusion criteria for the BVDV-negative population was a 
negative antigen capture ELISA (ACE) test on ear tissue (days -14 and -16 in studies one and 
two, respectively) and two negative serum VI tests (days -14 and -4, and days -16 and -6, in 
studies one and two, respectively).  All tests were performed at the Kansas State Veterinary 
Diagnostic Laboratory (KSVDL). 
In both studies, the inclusion criteria for the BVDV PI animal included two positive ACE 
(skin) and VI tests (serum) two weeks apart by the KSVDL.  In study one, one mixed breed beef 
steer calf was identified as PI during a previous KSU research study.  This calf weighed 
approximately 181.4 kg on day 0 of study one and had been isolated in an off-site facility prior to 
introduction.  In study two, the PI calf had been identified as potentially PI by a commercial 
feedlot in central Kansas.  This calf weighed approximately 363.6 kg on day 0 of study 2 and had 
remained at the aforementioned feedlot prior to introduction to the non-PI study population. 
Genotyping and subtyping analysis of both PI calves was completed by the KSVDL.     
On day 0 of both studies, the PI calf was commingled with the non-PI population. Blood 
was collected in two five mL red top clot tubes and two four mL EDTA tubes from each 
individual calf by jugular venipuncture.  One ear biopsy measuring approximately one cm2 was 
collected from each individual calf and placed in sterile plastic tubes.  One sterile nasal swabe 
was inserted approximately 10 cm (four inches) into the nostril, rested against the mucosal 
surface, and gently rubbed against the nasal mucosa in a circumferential pattern five times.  
Blood was collected in the same manner every other day for the duration of both studies.  Due to 
the frequency of jugular venipuncture, both jugular grooves were clipped prior to day 0, the side 
of blood collection was alternated between each timepoint, and the site of injection was cleansed 
with chlorhexidine and alcohol prior to needle insertion to minimize the risk of phlebitis.  Ear 
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biopsies and nasals swabs were collected every four days for the duration of both studies. Each 
PI calf remained with its respective population for 21 days after introduction.   
Within one hour of each sample collection, blood tubes were centrifuged at 2350 rcf (g) 
for 10 minutes and serum, plasma, and buffy coat were harvested in a traditional manner.  Buffy 
coat samples in study one failed to be collected until day 12 of the study; however, buffy coat 
was collected for the entirety of study two.  All specimens (serum, plasma, buffy coat, skin 
biopsies, and nasal swab samples) were stored at -80°C until further diagnostics were performed.   
Throughout both studies, animal caretakers offered a total mixed ration equating to 1.5% 
body weight (DMI) twice daily while grass hay and fresh water was offered ad libitum.  All 
calves were observed twice daily by a veterinarian to monitor individual health status.  Rectal 
temperatures and further examination of individuals suspected of clinical disease were attained 
prior to treatment.  Animals displaying clinical signs of respiratory disease and rectal 
temperatures ≥ 40° C were classified as individuals experiencing bovine respiratory disease 
(BRD) and were treated following a predesigned treatment protocol.  The treatment protocol 
dictated that cattle meeting the treatment criteria for BRD were treated with tulathromycine (2.5 
mg/kg SC), florfenicolf (40mg/kg, SC), and oxytetracyclineg (20mg/kg, SC) for the first, second, 
and third treatments, respectively.  The pen was idle for approximately two months between the 
two studies and during this time the watering devices and feed bunks were cleansed and 
disinfected and the pen floor was scraped and all organic material was removed. 
On the last day of both studies (day 21), the PI calf was removed from the pen.  The 
remaining non-PI calves were maintained at the study site until negative VI tests (on serum) 
were confirmed on all non-PI cattle.  Upon a cumulative VI negative status, all non-PI animals 
left the facility on the same day.   
Serology 
In both studies, serum neutralization assays for type one, type two, and the homologous 
PI BVDV were performed on serum at the KSVDL using the assay format as previously 
described.33  Antibody titers were quantified from serum samples from all calves from both 
studies on days 0 and 21.   
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Virus Isolation 
All quantitative VI attempts from both studies were conducted by student workers and 
completed in the KSVDL.  Samples for quantitative VI were subjected to four ten-fold serial 
dilutions and two hundred µLs of each respective sample/dilution were then added to freshly 
seeded embryonic bovine lung (EBL) cell cultures in 96 well micro-titer plates.  The assay plates 
were then incubated for 48 hours at 37oC in 4.5% CO2.  After incubation the media in each plate 
was discarded and the cells were washed with FA-PBS and fixed in an 80% aqueous acetone 
solution for 10 minutes.  After discarding the acetone, the plates were allowed to dry at room 
temperature.  An indirect fluorescent antibody test was used to detect BVD infected cells.  Fifty 
µLs of the primary anti-BVDV monoclonal antibody (D89)34 was added to each well and 
allowed to incubate for 30 minutes.  The primary antibody was then discarded and the plate 
washed with FA-PBS and fifty µLs of the FITC labeled secondaryi was added to each well and 
allowed to incubate for 30 minutes.  After incubation the secondary antibody was then discarded 
and the plate was washed with FA-PBS and fifty µLs of 50% glycerol were added to each well 
prior to reading the plates.  The cell-culture infectious dose (CCID-50) was calculated by the 
method of Spearman and Karber as previously described method.35     
Real-time Reverse Transcriptase Polymerase Chain Reaction 
RNA extraction of serum samples – One hundred µLs of serum from all calves were 
utilized for extraction of viral RNA for use in quantitative real-time RT-PCR (rRT-PCR) 
analysis. Magnetic bead based nucleic acid isolation method was used to extract Viral RNA 
using a commercial isolation kitj by following manufactures instructions.  A commercial 
processor and protocolk,l was utilized for RNA extraction with an elution volume of 90 µL. The 
RNA from the samples was stored at -80° C until use.  
RNA extraction of nasal swab samples – The nasal swab samples were vortexed at low 
speed for 10 seconds.  One hundred µLs of the sample was then utilized for RNA extraction by 
following the procedure as described above. 
Quantitative real-time RT-PCR (rRT-PCR) analysis – The rRT-PCR assay was 
performed using a commercial test kitm to identify BVDV RNA in the serum samples. The qRT-
PCR analysis was performed in a 25 µL reaction volume containing 2X RT-PCR buffer (12.5 
µL), 25X BVDV primer probe mix (1 µL ), 25X RT-PCR Enzyme Mix (1 µL), sample template 
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(8 µL) and nuclease free water (2.5 µL). The PCR analysis also included appropriate positive 
and negative controls. Commercial templatesn served as positive controls for the PCR reaction.  
A reaction containing all the reagents but no template was also included to serve as a negative 
control. The assay was performed in a commercial systemo under standard run mode.  Thermal 
profile for the PCR reaction included an initial cDNA synthesis step of 10 min at 45 °C followed 
by RT inactivation and initial denaturation step for 10 min at 95 °C, then 40 cycles of 95 °C for 
15 sec, and 60 °C for 45 seconds.  The rRT-PCR data analysis was performed with the help of 
commercial softwarep.  Prior to the data analysis, the rRT-PCR run was validated  by verifying 
the cycle threshold (Ct) values of positive and negative controls reactions (BVDV RNA target, 
Ct ≤ 28; Xeno RNA control target, Ct ≤ 31; and no-template control reaction, no signal or Ct = 
40).  The results were then interpreted based on Ct distributions per the manufacturer’s 
recommendationsl, where Ct ≤ 38 were considered positive, Ct values between 38-40 were 
considered suspect results, and Ct > 40 were considered negative. 
In both studies, the case definition for an animal at risk for becoming rRT-PCR positive 
included the timeframe from when the PI calf was introduced to the BVDV negative 
subpopulation (day 0) up until a positive test result was first confirmed among individual cattle.  
Therefore, when/if the calf displayed a positive PCR outcome, that respective calf was no longer 
at risk for positive PCR status.  Given that serum was collected every other day, the duration of 
positive PCR status was defined from the initial day of positive PCR status to the day prior to the 
first negative PCR test.  For example, if a calf had positive serum PCR results on days 8 and 10 
but tested negative on day 12, it would be classified as PCR positive  for a duration of three days 
(days 8 – 11).   
Statistical Analysis 
The individual calf was the experimental unit throughout the data analysis.  Descriptive 
statistics and graphical procedures for all measured variables were obtained by a commercial 
software packageq.   Assessment for normality among continuous distributions (day of TI onset 
and duration of TI) was performed by visual assessment as well as by formal statistical methodsr.  
As per standard practice, if continuous data were determined not to be normally distributed, the 
median value and range of data (not the average and standard error) was implemented as the 
necessary point estimate and description of data variation, respectively. 
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Results  
All screening phase (pre day 0) ear biopsies and serum samples from the non-PI calves in 
both studies were negative for BVDV.  The status of both PI animals was confirmed through 
ACE (on ear tissue) and VI (on serum).  In study one, a cumulative morbidity risk of 8.3% (1/12) 
was observed among the non-PI population while no morbidity (0%) was observed in study two.  
At arrival (pre day 0) 25% (n=3) of non-PI calves enrolled in study one were negative for type 
one and type two BVDV antibodies as well as antibodies to the homologous strain infecting the 
PI calf.  The remaining non-PI population (n=9) possessed antibodies to both BVDV genotypes 
as well as the homologous PI strain (Table 1).  On day 21 post-exposure, 41.8% (n=5), 16.7% 
(n=2), and 100% (n=12) of the non-PI calves displayed a four-fold rise in serum antibodies to 
BVDV type one, type two, and the homologous PI strain, respectively.  At arrival, 6.7% (n=1) of 
non-PI calves enrolled in study two were negative for both type one and type two BVDV 
antibodies as well as antibodies to the homologous strain possessed by the PI calf (Table 1).  Of 
the remaining non-PI population in study two, 40% (n=6) possessed antibodies to type one, type 
two, and the homologous PI virus, 20% (n=3) possessed antibodies to both BVDV genotypes but 
not the homologous PI virus, and 33% (n=5) possessed only BVDV type two titers.  By day 21 
of study two, 26.7% (n=4), 26.7% (n=4), and 60% (n=9) of the non-PI calves displayed a four-
fold rise in serum antibodies to BVDV type one, type two, and the homologous PI strain, 
respectively.   
Virus isolation performed on serum did not identify BVDV among the non-PI calves at 
any sampling point throughout the duration of both studies.  Serum VI tests from both PI calves 
in each respective study were positive on every day of sample collection with a range of serum 
BVDV concentrations of 101.70 – 103.70 CCID-50/mL of serum (Figure 1).  Similarly, VI 
performed on nasal swabs did not identify BVDV among the non-PI population; however, 
samples from study two displayed a relatively high degree of contamination.  Conversely, nasal 
swabs collected from the PI calves were positive by VI on days 16 and 20 in study one and days 
0, 4, 8, 12, 16, and 21 in study two.   
Due to the inability of VI to isolate BVDV in serum in either study, BVDV was 
successfully isolated from one buffy coat sample (the classical gold standard) of one randomly 
selected TI calf for genotyping and sequencing.  As expected, virus was detected and genetic 
sequencing determined that the homologous BVDV from each respective PI calf were 
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genetically different; however, each was classified as BVDV type 1b.  Additionally, isolated 
BVDV from the aforementioned TI cattle was homogenous with virus isolated from each 
respective PI calf in both studies (data not shown).   
Given the PCR manufacturer’s recommendation of Ct values indicating positive test 
results (Ct ≤ 38), 83.3% (n=10) and 80% (n=12) of the non-PI calves were serum PCR positive 
for BVDV nucleic acid at least once during studies one and two, respectively (Table 1).  The 
remaining calves in studies one (n=2) and two (n=3) were found to be PCR negative (Ct > 40) at 
all collection points.  However, 80% (n=4) of these PCR negative non-PI calves displayed a 
four-fold increase in serum antibodies to the homologous BVDV PI strain in their respective 
study indicating that they were indeed TI.   
Cumulatively, across both studies, 77.8% (14/18) and 88.9% (8/9) of non-PI calves with 
and without antibodies to the homologous PI strain of BVDV, respectively, became PCR 
positive to BVDV at some point during their respective study (Table 1).  The day of initial 
positive PCR status and subsequent duration were both determined not to be normally 
distributed.  Therefore, across both studies, the median day of the initial positive BVDV PCR 
diagnosis was day 10 (range: 6 – 21 days) post-exposure to the PI calf while the median duration 
of positive BVDV PCR status was 3 days (range; 1 – 9 days) (Table 1).     
In studies one and two, respectively, nasal swabs from 66.7% (8/12) and 80% (12/15) of 
non-PI cattle were found to be PCR-positive for BVDV at least once (Table 1).  Among the non-
PI calves that tested PCR positive on serum for BVDV, 70% (7/10) of calves in study one and 
91.7% (11/12) of calves in study two had positive nasal swabs.  Due to the infrequency of nasal 
swab collection, the time of onset and duration of PCR positive status of nasal swabs were not 
estimated.   
Discussion 
The results of this study indicate that BVDV is easily and rapidly transmitted from an 
individual recognized as PI with BVDV to non-PI individuals demonstrated by rRT-PCR and 
confirmed by seroconversion but not necessarily by VI from serum or nasal swabs.  The 
experimental method demonstrated in this study which included the method of exposure to 
BVDV by a PI calf, the procurement methods of the non-PI calves, and the broad distribution of 
individual BVDV antibody titers at arrival parallels typical scenarios encountered in stocker, 
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back-grounding, and feedlot production systems throughout the U.S.29-32,36  These attributes, 
coupled with the ability to measure natural BVDV transmission among PI and non-PI cattle by 
rRT-PCR analysis and confirmed by seroconversion, indicates that this model for evaluating 
BVDV transmission from PI to non-PI individuals is valid, reproducible, and offers advantages 
for evaluating natural BVDV transmission by co-mingling individuals.  
Diagnostic sensitivity of VI performed on buffy coat to diagnosis BVDV TI has 
previously been observed to be superior to that of serum.27,28  However, logistical concerns likely 
preclude private practitioners from collecting and submitting buffy coat.  Anecdotal reports (as 
well as our own clinical experience) suggest that serum provides the veterinarian with a more 
convenient and practical sample to collect and process (compared to buffy coat) thereby being 
the more likely specimen to be submitted to diagnostic laboratories.  Therefore, characterization 
of TI cattle by means of serum (not buffy coat) was determined to be the primary sample in the 
present study. 
These data suggest that cattle exposed to a PI BVDV individual can rapidly become TI 
with BVDV (as assessed by rRT-PCR on serum samples and indicated by a four-fold rise in 
BVDV antibody titers to the homologous PI strain) while lacking positive VI status in serum and 
discernible clinical disease.  These findings are complemented by positive rRT-PCR outcomes 
on nasal swabs denoting that BVDV nucleic acid was circulating in the population thereby 
serving as a potential source for further transmission to co-mingled cohorts.  Furthermore, the 
positive VI on buffy coat samples from selected TI calves matched the BVDV sequenced from 
the respective PI calves indicating that nucleic acid identified by rRT-PCR did originate from 
infectious virus shed by the PI calf in each study.  To our knowledge, this is the first report 
characterizing this form of TI of BVDV by natural exposure by co-mingling of non-PI 
individuals with PI individuals.  Previous studies depicting transient infections from natural 
BVDV exposure have isolated BVDV in serum and buffy coat by VI methods.25-28  However, 
our findings of a four-fold rise in serum antibody titers to the homologous BVDV strain shed by 
the PI calf (experienced by a majority of the non-PI sample population) coupled with positive 
rRT-PCR results among serum samples and nasal swabs is clearly indicative of BVDV 
circulating within in each group of non-PI calves. 
Despite the lack of positive serum VI findings among non-PI cattle in the present study, 
rRT-PCR results indicate that BVDV nucleic acid can be identified by rRT-PCR in serum from 
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days 6 – 21 post-PI exposure with subsequent duration of positive rRT-PCR results for 
approximately 3 – 4 days.  Brownlie et al. (1987) described that BVDV antibody-negative non-
PI cattle were viremic from days 4 – 7 post-BVDV.22    Unfortunately, this report does not 
provide the methodology of how BVDV exposure occurred (experimental or natural exposure) or 
how viremia was diagnosed (compared to antibody production and rRT-PCR findings in the 
present study); nonetheless, it does demonstrate a similar duration of TI (~ 3 – 4 days) with a 
tighter timeframe of TI onset than what was observed in the present study.  Conversely, previous 
authors have observed that BVDV could be isolated from the buffy coat of antibody diverse 
groups of non-PI calves from days 6 – 35 when exposed to PI cattle.27,28  This suggests that an 
immunologically diverse population of cattle (as in the present study) may display a high degree 
of variability in the timing of onset of BVDV.  This could be attributed to the pathogenicity of 
the virus shed by the PI animal, overall herd immunity, or by behavioral dynamics (i.e. 
differences in the rate of intermingling) that differ among populations.   
One potential variable leading to an inability to isolate BVDV by VI in serum among TI 
cattle may be attributed to the characteristics of BVDV shed by the PI calves.  The PI calves in 
both studies were infected with BVDV Type 1b; previously shown to be the type of highest 
prevalence in U.S. feedlots.37,38  These PI calves possessed quantifiable serum BVDV 
concentrations and positive nasal swab samples at multiple sample times indicating that they 
were both truly PI and currently shedding BVDV.  However, the quantity of BVDV in serum 
among the PI calves in the present study was relatively less (102 – 103 CCID-50/mL) when 
compared to previously reported serum BVDV concentration of PI cattle.3,25,26  Although a 
recent study proposed that BVDV concentrations in nasal swabs may be superior to that in serum 
or buffy coat for predicting the viral load shed into the environment,10 serum concentrations from 
the PI calves in the present study may indicate that low concentrations of BVDV were shed by PI 
cattle.  
In addition to the reduction in viral shedding by the PI calves (as described above), the 
lack of clinical disease in the present study may be partly explained by the antibody diversity of 
the study population.  Previous researchers have described variable results when attempting to 
measure the association between BVDV antibody status and the risk of BVDV infection.  A 
previous study failed to detect a significant association among VI outcomes and BVDV antibody 
status among non-PI calves.27  Conversely, antibody diverse non-PI cattle vaccinated with a 
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commercial BVDV vaccine were observed to have a reduced risk of becoming VI positive on 
buffy coat samples when compared to unvaccinated calves upon exposure to PI cattle.28  Further 
research in externally valid production environments is needed to quantify the effects of prior 
BVDV antibody production, either by natural infection or by vaccination, on incidence and 
duration of subsequent viremia and clinical disease following exposure to PI cattle shedding 
different genotypes and variable concentrations of BVDV.     
The nasal swab findings from the present study concur with prior research which 
observed a lack of BVDV detection (by VI) in nasal swab samples among non-PI cattle when 
exposed to PI calves.25,27,28  However, a previous study observed the ability of VI to identify 
BVDV shedding in nasal secretions among antibody-negative TI cattle upon prolonged exposure 
to a PI calf.26  Although the ability of TI cattle to infect non-PI cohorts was not measured in the 
present study, positive rRT-PCR results on nasal swab samples from the non-PI population (with 
variable levels of BVDV antibodies to the homologous PI strain) suggest that BVDV (or at least 
viral nucleic acid) was being shed in nasal secretions potentially affording TI cattle the capability 
of transmitting the virus.  Previous studies have observed that TI cattle can potentially transmit 
BVDV to susceptible populations over long durations with and without the presence of PI 
cattle.26,39,40  These data suggest that BVDV transmission may not only be associated with virus 
excreted from PI cattle but that TI cattle may contribute to viral transmission.  Nonetheless, 
further research is warranted to determine the role that TI cattle play in the transmission of 
BVDV within production systems.   
Prior research has associated PI cattle with clinical disease and performance loss in both 
the cow-calf and feedlot sectors of the beef industry.41-44  However, other authors have 
demonstrated that the presence of PI cattle did not pose a negative health or performance threat 
to non-PI cattle in the same pen.36-39  Prior reports, as well as the present study, demonstrate the 
potential variation in health and performance outcomes that may be experienced by cattle 
populations when PI cattle are present.  Despite the lack of clinical disease in this study, the high 
percentage of cattle becoming TI indicates that subclinical BVDV infections may be more 
prevalent than previously described.45  Unfortunately, we were unable to capture individual 
weights of calves in either study to determine average daily gain and the potential association of 
transient BVDV infections with performance loss despite a lack of clinical disease.  Therefore, 
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further research will be needed to determine the prevalence of subclinical, transient BVDV 
infections and the potential impacts on feed performance and carcass characteristics.  
The disease transmission model used in the present study was twice observed to be an 
effective means of studying viral transmission characteristics of BVDV among PI cattle and 
immunologically heterogeneous populations of non-PI cattle.  This model simulates current 
industry management practices thereby providing a relatively high degree of external validity to 
the conclusions of the research.  The findings indicate that when commingled non-PI cattle are 
exposed to a PI individual, they can become TI to BVDV based on rRT-PCR and seroconversion 
(in our study indicated by a four-fold rise in α-BVDV antibodies to the homologous BVDV 
strain recovered from the PI individual).  Results of BVDV rRT-PCR  indicates that BVDV 
nucleic acid can be identified in the serum of co-mingled cattle beginning approximately 6 days 
post-exposure to the PI calf and remaining for approximately 3-4 days in duration.  These 
findings were observed despite a lack of positive serum VI findings or clinical disease.  The lack 
of both observable clinical disease and inability to isolate BVDV may have been attributed to the 
variability in preexisting antibody titers to BVDV among the non-PI calves and unknown 
strain/virulence characteristics of the BVDV being shed by the PI calves used in this study.  Our 
data indicates that VI performed on serum and nasal swabs may lack the sensitivity for 
diagnosing many transient BVDV infections.  Additionally, our results indicate that BVDV 
transmission from PI individuals can occur rapidly to co-mingled individuals without overt 
clinical disease that might be an indicator of exposure.  These results also indicate that we as 
veterinary professionals might need to reassess our timetable for testing to define PI BVDV 
individuals if the rationale for PI testing is to limit BVDV transmission to a naive or susceptible 
population.  Current testing is often completed after extensive co-mingling of animals of 
unknown status in stocker, back-grounding, and feedlot production systems.  These results would 
indicate that exposure to PI individuals in these scenarios might be too late to avoid the 
consequences of BVDV transmission and infection on other co-mingled individuals.  This 
approach might indicate and justify earlier PI-BVDV testing (i.e. at the cow-calf production 
level).    
Despite a lack of positive VI findings on serum and nasal swab samples among the non-
PI sample population, numerous positive serum and nasal rRT-PCR results (and limited VI on 
buffy coat samples) could be generated from these samples and seroconversions of all non-PI 
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individuals evaluated in these studies, strongly supports our conclusions that BVDV infections 
with accompanying viral shedding occurred among non-PI cattle in this study due to co-mingling 
with a PI individual.  Cattle TI with BVDV may contribute to enhanced BVDV transmission to 
additional co-mingled animals under these conditions; however this was not evaluated in the 
current study.   
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Sources and Manufacturers 
a.  Vision 7®, Intervet/Schering Plough Animal Health, The Netherlands 
b.  Dectomax®, Pfizer Animal Health, Kalamzoo, MI 
c.  Prozap® Insectrin® Pour-On XTRA, Chem-Tech, LTD., Des Moines, IA 
d.  Large Ear Notcher, Stone Manufacturing, Kansas City, MO 
e.  BD Universal Viral Transport, cat.# 220221, Becton, Dickinson & Co., Sparks, MD, 21152 
f.  Draxxin®, Pfizer Animal Health, Kalamzoo, MI 
g.  Nufor®, Intervet/Schering Plough Animal Health, The Netherlands 
h.  Biomycin 200®, Boehringer Ingelheim, Saint Joseph, MO 
i.  Fluorecscen (FITC) conjugated Affini Pure Goat Anti-Mouse IgG (H & L), code # 115-095-     
    003, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA  
j.  MagMaxTM-96 Viral RNA Isolation kit, Ambion, Austin, TX 
k.  MagMax Express® magnetic particle processor, Applied Biosystems, Austin, TX 
l.  Magmax Express 96 protocol AM1836_dw_100V2, Applied Biosystems, Austin, TX 
m. BVD RNA Test kit, Applied Biosystems, Austin, TX 
n.  25X BVDV Control RNA and Xeno™ RNA control, Applied Biosystems, Austin, TX 
o.  7500 Fast Real-Time System, Applied Biosystems, Austin, TX 
p.  7500 SDS (v1.4) software, Applied Biosystems, Austin, TX 
q.  Microsoft Excel®, 2003, Redmond, WA 
r.  Proc Univariate, SAS (version 9.1), Cary, NC 
 59
Table 4.1:  Individual animal outcomes among the non-persistently infected calf population 
across studies one (n=12) and two (n=15).  Serum and nasal swabs were collected every 
other day and every fourth day (including day 21), respectively.  Cumulative serum and 
nasal swab PCR status reflects the individual animal status at day 21 (post PI 
introduction). 
Calf Study Antibody titer 
to homologous 
PI BVDV strain 
at arrival 
Cumulative 
Serum PCR 
status 
Day of 
positive 
PCR Onset 
Duration of 
positive 
PCR status 
(days) 
Cumulative 
Nasal Swab 
PCR status 
1 1 0 + 8 2 + 
2 1 0 + 10 3 - 
3 1 0 + 8 7 - 
4 1 8 + 10 2 + 
5 1 8 + 10 3 - 
6 1 16 + 8 2 + 
7 1 16 + 16 2 + 
8 1 16 + 6 3 - 
9 1 16 - Not available Not available + 
10 1 64 + 6 5 + 
11 1 64 - Not available Not available + 
12 1 128 + 6 3 + 
1 2 0 + 14 2 + 
2 2 0 + 12 3 + 
3 2 0 + 10 3 + 
4 2 0 + 6 3 + 
5 2 0 + 8 3 + 
6 2 0 + 8 7 + 
7 2 0 + 8 9 - 
8 2 0 + 10 9 + 
9 2 0 + 10 9 + 
10 2 8 + 14 2 - 
11 2 8 - Not available Not available + 
12 2 8 - Not available Not available + 
13 2 16 + 12 2 - 
14 2 32 + 21 1 + 
15 2 256 - Not available Not available + 
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Figure 4.1: Individual serum BVDV concentrations for the PI calves in studies one and two 
at each sample collection time point across a 21 day study period.  The cell-culture 
infectious dose50/ml (CCID-50) values (y-axis) reflect serum viral concentration in log10 
format (e.g. log10 3 = 103). 
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CHAPTER 5 -  Bovine Viral Diarrhea Virus (BVDV) 
Status in cow-calf herds, its association with biosecurity 
practices, and the association of these practices with self-
perceived understanding of BVDV among Montana beef 
producers 
Introduction 
Bovine viral diarrhea virus (BVDV) has long been recognized as a pathogen with the 
ability to manifest in a variety of clinical syndromes.139,153,230,231  The viral reservoir, cattle 
persistently infected (PI) with the virus, are created by in utero infection occurring during days 
45-125 of gestation and are thereby lifelong shedders of BVDV.56  Therefore, the creation of PI 
cattle in both beef and dairy production systems can be attributed to the maternal segments of 
each respective industry.   
Numerous tools have been implemented to minimize production losses attributed to PI 
cattle among herd and pen mates.  Currently, several testing modalities are commercially 
available for identification of individual PI cattle.83,145,146,148-150,153  Additionally, vaccination 
programs are considered an important component of most BVDV control programs within the 
United States and are intended to elevate herd immunity and reduce the risk of fetal 
infection.159,161,176,232  Prevention of BVDV introduction into a beef herd is also an important 
attribute of BVDV control programs.  Biosecurity has previously been defined as the efforts to 
prevent the introduction of pathogens or toxins that have the potential to damage the health of a 
herd of cattle or the safety of a food product.157  Therefore, biosecurity programs focus on 
minimizing the risk of pathogen exposure by implementing specific cattle management and 
procurement practices.155    
The Montana BVD-PI Herd Biosecurity Project was created in 2006 as a segment of the 
Montana Beef Quality Assurance program.  The overarching goal of this program is to reduce 
the risk of introducing BVDV into Montana beef herds by providing cow-calf producers with 
BVDV education, BVDV herd risk assessment, testing protocols to screen herds for PI cattle, 
and strategies to optimize herd biosecurity and management.233  The data compiled from this 
project provides a unique opportunity to estimate the relationship among common management 
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practices and herd BVDV status.  These findings can potentially be implemented into current 
BVDV preventative and control programs in order to modify and/or strengthen current 
recommendations. 
The objective of this study was three-fold:  1) estimate the herd and within-herd 
prevalence of BVDV among program participants in Montana, 2) estimate the distribution of 
specific management practices of beef cow-calf participants during the three years prior to their 
individual involvement in the program and determine if significant associations are present 
among the management practices of cow-calf herds and herd BVDV status, 3) determine if 
associations are present between the individual producer’s perceived knowledge of BVDV and 
the implementation of specific management practices. 
Materials and Methods 
Sample Population 
Implemented in 2006, the Montana BVD-PI Herd Biosecurity Project is a voluntary 
program open to all beef producers within the state of Montana.  Upon herd enrollment, 
producers were provided with the necessary materials for sample collection based on the number 
of animals stated by the producer that would be tested for BVDV.  Individual animal diagnosis 
was performed by a previously described technique149,150 currently offered by a private 
commercial laboratorya.  Individual animal results were communicated to both the producer and 
the project coordinators.  Test results and management considerations were then discussed 
among the herd owner, the project coordinators, and the herd veterinarian to determine the 
optimal management protocol given the herd BVDV status. 
The sample population in this study included all past and active participants of the 
Montana BVD-PI Herd Biosecurity Project since its inception in 2006 and extending through 
2009.  The authors were supplied with individual herd information consisting of herd size, 
classes of cattle tested for BVDV, and annual BVDV test results thereby providing the means to 
classify herds as either of BVDV positive or negative status and determine within-herd BVDV 
prevalence among participating herds.  All herds were subsequently surveyed to evaluate 
objectives 2 and 3. 
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 Survey Instrument 
The survey consisted of six open and seven nominal scalar (closed) questions designed to 
capture information regarding various cow-calf herd management practices.  The questions were 
designed to determine herd size (1 question), replacement female/male procurement and 
management practices (3 questions), BVDV vaccination implementation and timing of 
administration (2 questions), procurement and management of stocker cattle in relation to the 
resident herd (2 questions), communal grazing practices of the resident herd (2 questions), the 
practice of transporting cattle off-site followed by reintroduction to the resident herd (2 
questions), and individual understanding of BVDV and its effect on production systems (1 
question).  To maintain anonymity but yet provide identification, each participant was randomly 
assigned a unique number, produced by a commercial software packageb, and merged onto their 
respective survey.  This survey was approved by the Kansas State University Committee for 
Research Involving Human Subjects Institutional Review Board.  A copy of the 4-page survey 
may be obtained from the authors upon request.   
 Survey implementation 
In order to contact the program participants, home addresses were obtained from the 
Montana State University Beef Quality Assurance program.  Upon receipt of the survey, each 
respondent was requested to return the completed survey within 30 days of receipt.  All surveys 
were returned to the co-author (CP; in Montana) and subsequently delivered to Kansas for data 
entering and analysis.   
 Statistical analysis 
The experimental unit was the herd throughout all analyses and the case definition of a 
positive herd was a herd previously diagnosed with ≥1 PI animal (yes or no) during its tenure in 
the Montana BVD-PI program.  Potential associations were evaluated between survey responses 
(independent variables) and both herd BVDV status and herd self assessment of BVDV 
knowledge (dependent variables).  Data were entered into a commercial software packageb and 
descriptive statistics were calculated.  Independent categorical variables displaying sparse data 
within individual levels were collapsed with adjacent categories to provide sufficient numbers of 
observation among levels.  Linearity between the remaining continuous independent variables 
and dependent variables was assessed by categorizing the continuous variable by quartiles or 
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natural breaks in the data and analyzed by commercial softwarec; continuous independent 
variables failing to demonstrate linearity remained as categorical variables.  Evidence of 
correlation was assessed by correlation matrices (continuous responses) as well as contingency 
tables (categorical responses).  Correlation of ≥ 0.4 (continuous variables) or a significant 
association among two (categorical) variables (P <0.05) were considered potentially collinear.  
Among all models, each independent variable was assessed for association with the dependent 
variable by bivariable models using a liberal p-value (≤ 0.25)d.  A forward step-wise model 
building procedure was then implemented to determine a final multivariable model; an alpha 
level of 0.10 was used for inclusion.  Potential confounders were analyzed by measuring the 
change in the coefficient of the covariate of interest; a numerical modification of the coefficient 
by ≥ 20% (when the potential confounder was added to the model) suggested that significant 
confounding was present.  Confounding variables were retained in the model regardless of 
statistical significance.  All biologically plausible two-way interactions were also assessed 
following determination of main effects.   
Results 
Descriptive BVDV outcomes among project participants 
From 2006 through 2009, 585 beef herds voluntarily enrolled in the Montana BVD-PI 
Herd Biosecurity Project.  The number of herds joining the program (for the first time) on an 
annual basis was 49 (8.4%) in 2006, 411 (70.3%) in 2007, 92 (15.7%) in 2008, and 33 (5.6%) in 
2009, respectively.  These participating herds represent 5.2% of the beef herds in the state of 
Montana.234  Among the herds participating in the program, 38 were determined to possess ≥ 1 
PI animal; thus, a herd BVDV prevalence of 6.5% (95% Confidence Interval [95% CI], 4.5% –  
8.5%].  The within-herd prevalence among these 38 positive herds ranged from 0.12% – 20.0% 
with a median value of 0.75% (Figure 5.1).  Although not statistically evaluated, clustering of PI 
cattle among individual herds was evident as 68.4% (n=26) of BVDV positive herds detected > 1 
PI animal at the time of testing. 
Survey outcomes in the present study 
Of the 585 herds enrolled in the program from 2006 – 2009, 563 had BVDV results and 
were subsequently contacted to participate in the survey.  Of these, 230 herds completed and 
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returned the aforementioned survey (40.9% response).  Respondents included 95.7% (n=220) 
BVDV test-negative herds and 4.3% (n=10, 95% CI; 1.7%, 7.0%) BVDV positive herds. 
Herd Size – The distribution of herd size among the survey respondent population is 
displayed in Table 5.1.  Upon analysis, this variable was categorized by quartiles.   
 Replacement female/male procurement and management practices – Producers were 
asked to provide the number of purchased heifers, yearling bulls, pregnant heifers, pregnant 
cows, as well as home-raised heifers and bulls (raised off-site) that were subsequently introduced 
to the resident herd (Table 5.1).  Upon analysis, data were categorized into individual binary 
formats (yes or no) thereby indicating whether producers either did or did not engage in 
procuring the above classes of cattle (Table 5.2).  Among the respondents to this question, 82.5% 
(n=198/240) stated that they annually imported ≥ 1 of the aforementioned classes of cattle to the 
resident herd.   
Among producers indicating importation of cattle, 33.8% (n=86/198) stated that they 
annually introduced pregnant females (heifers and/or cows) to the herd.  Among these herds that 
import pregnant cattle, 91.9% (n=79) disclosed the method of procurement of pregnant heifers 
and/or cows.  Of these individuals, 19.0% (n=15), 57.0% (n=45), and 24.1% (n=19) indicated 
they procured pregnant females outside of the resident herd  by means of auction markets, 
private treaty, or both methods, respectively.  
Respondents who imported cattle were asked to state the length of time (if any) that each 
of the above classes of cattle (excluding home-raised heifers and bulls) were quarantined from 
the resident herd prior to introduction (Table 5.1).  Given the low number of responses, the 
distributions of the given data, and previous research estimating the length of transient infection 
of BVDV,63,66,67 the above data was subsequently categorized in a binary format and analyzed to 
have (or have not) quarantined cattle > 14 days from the resident herd prior to introduction.  
Open heifers, yearling bulls, pregnant heifers, and pregnant cows were isolated for greater than 
14 days prior to introduction to the resident herd in only 31.9% (n=7/22), 39.5% (n=51/129), 
35.6% (n=16/45), and 36.4% (n=16/45) of respondent herds, respectively. 
BVDV vaccination and timing of administration – Among the respondents, 88.3% 
(n=190/215), 85.1% (n=86/101), and 76.9% (n=90/117) indicated that BVDV vaccine was 
annually administered to the cattle within the resident herd, home-raised replacement 
heifers/bulls (raised off-site), and leased/purchased replacement cattle, respectively, during the 
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three years prior to enrollment in the program.  Among the entire respondent population (n=230), 
49.2% (n=91), 30.8% (n=57), and 20.0% (n=37) indicated that BVDV vaccine was administered 
prior to breeding, at pregnancy diagnosis, or at both timepoints, respectively. 
Procurement and management of stocker cattle – Among those that responded to this 
question (n=220), 10% (n=22) indicated that they had purchased stocker cattle during this 
timeframe.  Among these 22 herds who purchased stocker cattle, 72.7% (n=16) indicated that the 
stocker cattle shared a pasture or had fenceline contact with the resident herd at some time point 
from breeding to weaning (i.e. were in contact with pregnant cattle).   
Communal grazing practices – Descriptive statistics for respondents who allowed 
fence-line access and pasture-sharing among neighboring herds and the resident herd anytime 
during the breeding season through the weaning period are displayed in Table 5.1.  Due to the 
low number of respondents indicating that pasture sharing did occur, no further analysis was 
performed on these data.  Among respondents who indicated that fence-line access to 
neighboring herds did occur, data were categorized based upon fence-line exposure to 0-2, 3, 4, 
> 4 herds.  Among respondents in the first (n=84), second (n=55), third (n=30), and fourth 
(n=53) categories, 15.6% (n=13), 22.8% (n=13), 35.3% (n=11), and 37.3% (n=20) indicated, 
respectively, that exposure to pregnant cattle within the resident herd occurred due to fence-line 
contact with neighboring herds. 
Transporting cattle off-site and reintroduction to the resident herd – The number of 
respondents to this question regarding the various classes of cattle allowed to leave the premise 
and subsequently return to the resident herd is located in Table 5.2. 
 Participant understanding of BVDV – Among the respondents to a question regarding 
their understanding of BVDV (n=217), 73.0% (n=159) perceived themselves to be “fairly 
knowledgeable” in regard to BVDV, 26.1% (n=57) “knew some basics”, and 0.9% (n=1) 
“recognized the name, BVDV”.  Due to the small number of responses in categories three, this 
last level was not included in further analyses.    
Association of survey outcomes and herd BVDV status 
Upon multi-variate analysis, herd BVDV status was associated (P<0.10) with the practice 
of annually vaccinating home-grown heifers and bulls (raised off-site) that are subsequently 
introduced to the resident herd (odds ratio [OR]=0.155, 95% confidence interval [CI]; 0.02-1.2).  
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Therefore, herds that annually vaccinated this class of cattle prior to introduction to the resident 
herd displayed approximately an 85% reduction in the risk of being BVDV positive.  Although 
herd size was not significant, respondent herds possessing ≥ 1000 cows (n=12) harbored 25% 
(n=3) of the BVDV positive herds participating in the survey.  All remaining survey outcomes 
were not significantly associated (P>0.10) with herd BVDV status in the final model.   
Association of perceived understanding of BVDV and herd biosecurity practices 
A multi-variate model consisting of all herd management practices was then analyzed 
with regard to perceived knowledge of BVDV (i.e. producers that perceived themselves as 
“fairly knowledgeable” or “know some basics” about BVDV).  Only covariates included in the 
model are discussed; therefore, reported data reflect model-adjusted estimates.   
In this model, herd size was significantly associated (P<0.10) with producer BVDV 
knowledge.  Upon further analysis, this difference was observed to be driven predominately 
when comparing the fourth quartile (herd with > 375 cows) to the bottom three quartiles.  These 
findings suggest that producers of herd sizes > 375 cows were significantly more likely (P<0.10) 
to perceive themselves as “fairly knowledgeable” with regard to BVDV (OR=1.9; 95% CI, 1.1 – 
3.2) when compared to all other categories. 
Annual BVDV vaccine administered to the resident herd was significantly associated 
(P<0.10) with perceived knowledge of BVDV (OR=2.7; 95% CI, 1.2-6.2).  Therefore, herd 
owners that annually vaccinate the resident herd for BVDV are 2.7 times more likely to perceive 
themselves as “fairly knowledgeable” in regard to BVDV.   
Communal grazing practices from breeding to weaning were significantly associated 
(P<0.10) with perceived knowledge of BVDV (OR=0.45; 95% CI, 0.21 – 0.98).  Therefore, 
program participants who engage in communal grazing are 55% less likely to perceive 
themselves as “fairly knowledgeable” with regard to BVDV. 
The practice of transporting pregnant heifers off-site and subsequently reintroducing 
them to the resident herd was also significantly associated (P<0.10) with being “fairly 
knowledgeable” with regard to BVDV (OR=14.7; 95% CI, 1.8 – 118.6).  This suggests that 
producers who engage in this activity are 14.7 times more likely to perceive themselves as being 
relatively educated with regard to BVDV.   
Discussion 
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Herds in the Montana BVD-PI Herd Biosecurity Program had a BVDV herd prevalence 
of 6.5%.  This finding is similar to previous studies that have determined herd BVDV prevalence 
among U.S. beef herds as well as those in western Canada.3,8,154  However, to our knowledge, 
this is the first report providing herd prevalence data specifically for the state of Montana.  
Therefore, these findings from the present study suggest that only a small percentage of beef 
herds in the state of Montana are BVDV positive.  However, given the distribution of within-
herd PI prevalence, approximately 65% of BVDV positive herds possess > 1 PI animal; 
therefore, PI cattle tend to be clustered in a small percentage of herds as outlined elsewhere.3  
Although the findings from this study highlight specific management practices 
implemented by participating herds, BVDV herd status was not shown to be associated with 
management practices previously recognized as risk factors for introducing BVDV to the 
resident herd.  Given that the BVDV herd prevalence in the present study (6.5%) is low, these 
outcomes may be attributed to loss of statistical power thereby elevating the risk of type two 
errors.   
Despite the lack of statistical associations of herd practices with BVDV status, the 
findings from the present study suggest that a large proportion of the participating herds engage 
in management practices previously described as having the potential to elevate the risk of 
disease introduction.157,158,235  Smith et al 2009 reported that importation of pregnant beef heifers 
was a significant risk factor regarding the introduction of BVDV to resident herds when 
evaluated by a stochastic model.155  In the present study, approximately 34% of respondents 
indicated that pregnant females had been previously brought into the herd within three years of 
enrolling in the program.  Although importing cattle into the resident herd increases the risk of 
disease introduction, implementation of quarantine procedures may help reduce the probability 
of this occurrence by allowing time for transient infections to wane, vaccines to be administered 
and take effect, and for diagnostic tests to be performed.  In addition to exposing the resident 
herd to outside sources of cattle, 25.5% of respondent herds in the present study indicated that 
they participated in communal grazing activities.  This estimate closely parallels survey data in a 
previous report regarding western U.S. beef producer’s participation in some variety of 
communal grazing (24%).157   This practice is common among states in the western U.S. and is 
necessary for providing adequate levels of forage to cow herds during the grazing months.  
Therefore, communal grazing is not likely to be curtailed solely due to its effect on the risk of 
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BVDV introduction.  However, the obvious hazard of communal grazing is attributed to the 
commingling among multiple herds thereby increasing the risk of disease transmission.  
Instituting biosecurity measures such as herd testing protocols for BVDV (prior to commingling) 
and quarantine protocols prior to reintroduction may reduce the risk of introducing economically 
devastating disease syndromes to the resident herd. 
In the present study, annually administering BVDV vaccine to home-grown heifers and 
bulls prior to introduction to the resident herd significantly reduced the risk of a positive herd 
BVDV status.  In heifers, the introduction of BVDV to the herd may be attributed to the 
production of PI calves.  Pre-breeding administration of BVDV vaccine to heifers should not be 
viewed as the sole element of BVDV prevention; however, prior research has displayed 
significant reduction in fetal infection and subsequent PI calf production among vaccinated 
heifers when compared to unvaccinated controls.113,159,161,173,175,176,236   
In the present study, owners of larger herds (> 375 cows) were significantly more likely 
to perceive themselves as “fairly knowledgeable” with regard to BVDV.  Potential reasons for 
this finding could be that the cow-calf enterprise of larger producers is their primary source of 
income; therefore, these individuals may be more likely to be familiar with BVDV due to greater 
exposure to their herd veterinarian and a greater interest in the beef industry (compared to 
smaller producers).  Alternatively, simply due to sheer numbers, larger herds may be more likely 
to have previously experienced actual clinical effects associated with BVDV than smaller herds, 
subsequently forcing them to be highly aware of BVDV.  In addition to herd size, the data in the 
present study suggest that producers who understand BVDV may avoid certain management 
practices that potentially increase the risk of disease introduction.  Beef producers in the present 
study who considered themselves “fairly knowledgeable” in regard to BVDV were more likely 
to institute annual BVDV vaccine programs within the resident herd and avoid communal 
grazing during the timeframe of breeding to weaning.  This suggests that prior BVDV education 
(coming from numerous potential sources such as first-hand experience with BVDV, experiences 
of other producers, veterinarian consultation, as well as state and national organizations) has 
improved client understanding and compliance with BVDV control protocols.  These findings 
contradict a previous study that observed a poor association between producer knowledge and 
compliance with BVDV control programs.237   
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Conversely, in the present study, producers indicating a high level of BVDV knowledge 
were significantly more likely to transport pregnant heifers off-site while subsequently 
reintroducing them to the resident herd at a later time.  Without proper precaution, this practice 
may be hazardous due to the unknown PI status of the unborn fetus upon return.  These findings 
suggest that either beef producers don’t recognize this practice as being a potential biosecurity 
risk or other constraints such as pasture management, breeding/calving supervision, labor 
allocation, or forage availability forces herds to adopt this practice in order to optimize herd 
production.  One preventative measure aimed to potentially reduce the risk of BVDV 
introduction by this practice would be segregate pregnant heifers upon return to the resident herd 
until both the heifer and calf are confirmed free of BVDV.  This final variable signifies that 
continued education is needed at the herd level in order to reduce the risk of BVDV introduction. 
Despite the present findings, sources of bias were likely present in this study.  Non-
response bias may have been introduced as herds previously diagnosed as being BVDV positive 
may have been less likely to participate in the present study.  Analysis of the non-response 
among BVDV positive herds (73.9%, 95% CI; 59.0%, 88.4%) compared to the non-response 
among BVDV negative herds (59.6%, 95% CI; 55.5%, 63.7%) indicates that these two 
proportions are not significantly different.  Additionally, further analyses comparing the 
aforementioned herd prevalence estimate for the respondent population (4.3%; 95% CI, 1.7% -- 
7.0%) and that of the non-respondent population (8.4%; 95% CI, 5.4% -- 11.4%) indicate that the 
proportion of BVDV positive herds among respondents and non-respondents were not 
statistically different.  This evidence suggests that non-response bias did not significantly alter 
the estimates in the current study. Recall bias may have impacted this study as participants were 
asked if certain management practices were being utilized three years prior to volunteering in the 
Montana BVD-PI program.  Therefore, given the year this program was founded (2006), it is 
likely that some participants may be unable to specifically remember how long a management 
practice has been employed or when it was begun thereby potentially affecting the accuracy of 
individual responses.  Survey respondents did not consist of a random sample as the study 
population consisted of herds that voluntarily participated in the Montana BVD-PI program.  
Nonetheless, geographical distribution of BVDV positive herds (data not shown) displayed a 
relatively uniform distribution throughout the state of Montana; therefore, it is likely that the 
survey responses of positive herds in the present study would be typical of other positive herds.  
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Likewise, herd BVDV status was determined a priori of the present study.  However, closer 
inspection of diagnostic records indicated that a small number of herds failed to test the calf 
population and tested only replacement cattle or the mature cows (i.e. failing to test the 
subpopulation [i.e. calves] at greatest risk of housing PI cattle).  Therefore, the present herd and 
within-herd prevalence estimates may be slightly underestimated.  Lastly, due to the cross-
sectional nature of this study, we are unable to determine if reverse causation was present due to 
the inability of determining if the modeled fixed effects (e.g. BVDV vaccination of home-raised 
replacement heifers) occurred before or after the modeled response variables (e.g. herd BVDV 
status). 
In summary, the present data suggests that a small percentage of beef herds in Montana 
are infected with BVDV.  However, among those positive herds, the within-herd distribution of 
PI cattle is large thereby suggesting that PI animals are indeed clustered at the level of the farm.  
These data also provide evidence that many beef producers in Montana currently engage in 
management practices that may elevate the risk of eventual disease introduction.  Veterinarians 
and beef producers must constantly assess their production practices and determine if a 
biosecurity risk is present.  However, instituting any biosecurity program must be determined to 
be of economic benefit to the producer based upon the prevalence of the disease and the 
individual producer’s risk aversion to the pathogen.  Continued persistence among veterinarians, 
academic institutions, extension services, and state and national organizations is necessary to 
maintain and improve producer education to optimize BVDV control and prevention.   
 72
 
Sources and Manufacturers 
a. Animal Profiling International, Inc., Portland, OR 
b. Microsoft Excel®, 2007, Redmond, WA 
c. Proc GLM, SAS (version 9.1), Cary, NC 
d. Proc Logistic, SAS (version 9.1), Cary, NC 
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Figure 5.1:  Within-herd prevalence of PI cattle among all BVDV positive herds (n=38) 
voluntarily enrolled in the Montana BVD-PI Biosecurity Program from 2006 – 2009. 
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Table 5.1:  Descriptive statistics of continuous variables among the respondent population 
(n=230) that provided answers to the following questions. 
Survey Question 
# of Respondent 
herds 
Mean Median S.D.* Minimum 
Observation 
Maximum 
Observation 
Herd Size 229 323 200 399 3 3000 
Cattle (purchased or home-grown) raised off-site and introduced to resident herd 
heifers 213 6.4 0 40.3 0 500 
yearling bulls 223 3.0 2 4.8 0 40 
pregnant heifers 215 6.0 0 25.8 0 300 
pregnant cows 211 8.0 0 30.0 0 250 
home-raised heifers and bulls 212 30.0 0 60.0 0 375 
Number of days that purchased cattle are quarantined prior to introduction to 
resident herd 
heifers 22 19.0 10 27.0 0 90 
yearling bulls 129 19.0 7 27.0 0 180 
pregnant heifers 45 16.0 10 20.0 0 90 
pregnant cows 44 12.0 10 14.0 0 60 
Number of neighboring herds 
allowed fenceline contact with 
resident herd               
(breeding to weaning) 222 3.5 3 2.5 0 15 
Number of neighboring herds 
that shared pasture with 
resident herd                 
(breeding to weaning) 225 0.6 0 1.5 0 10 
Number of days that home-raised cattle, transported off-site, are quarantined prior 
to introduction to resident herd 
Heifers (breeding) 27 39.4 0 79.3 0 365 
Heifers (exhibition) 14 2.5 0 5.2 0 14 
Pregnant Heifers 28 13.0 0 38.3 0 180 
Pregnant Cows 45 8.2 0 24.6 0 125 
Bulls 55 13.9 0 41.8 0 250 
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Table 5.2:  Descriptive statistics of categorical variables among the respondent population 
(n=230) that provided answers to the following survey questions. 
Survey Question 
Number of 
Respondents 
(herds) 
Did the herd engage 
in the management 
practice? 
   Yes (%) No (%) 
Replacement cattle leased, 
purchased, or raised off-site and 
introduced to resident herd  
   
heifers 213 11.3% 88.7% 
yearling bulls 223 66.1% 33.9% 
pregnant heifers 215 21.3% 78.7% 
pregnant cows 211 19.1% 80.9% 
home-raised heifers and bulls 212 43.0% 57.0% 
Transporting cattle off-site with 
subsequent reintroduction to resident herd 
   
heifers (for breeding) 218 10.6% 89.4% 
heifers (for exhibition) 214 5.6% 94.4% 
pregnant heifers 219 11.0% 89.0% 
pregnant cows 221 15.4% 84.6% 
bulls 222 19.4% 80.6% 
 
 
 76
 
CHAPTER 6 - Quantification of the Value of 
Implementing Whole Herd Testing Strategies in U.S. Beef 
Herds 
Introduction 
Bovine viral diarrhea virus (BVDV) is an endemic disease of the U.S. beef herd with the 
potential to clinically manifest by numerous pathways.  The virus has been observed to adversely 
affect cow-calf herds by inflicting reproductive wastage,1-4 elevate the incidence of morbidity 
and mortality,1-4 and reduce weaning weight.1  One unique aspect of BVDV is its carrier state 
which consists of cattle persistently infected (PI) with the virus.  Cattle PI with BVDV are 
created by in utero viral exposure during days 42 – 125 of gestation.5  Upon parturition, these 
animals shed the virus in all bodily secretions and excretions thereby increasing the risk of 
exposing non-PI cattle to BVDV.5-8  Therefore, one primary goal of BVDV control programs is 
to identify and eliminate PI animals from the herd.9-12 
Given the negative effects associated with BVDV and the economic ramifications associated 
with its presence, numerous testing modalities have been developed in order to accurately 
identify PI cattle.  These testing methods include immunohistochemistry (IHC) on formalized 
skin tissue,13-18 antigen-capture ELISA (ACE) on the phosphate-buffered saline (PBS) fraction of 
PBS soaked skin tissue,15,16,19-21 and real-time polymerase chain reaction (PCR) performed on 
fresh skin tissue.22  Although these tests are relatively accurate at discerning among PI and non-
PI cattle, very little data exists for comparison of test strategies (i.e. one single test versus two-
test protocols interpreted in series).    
Current recommendations suggest that cow-calf herds at high risk of being positive for 
BVDV should institute a whole herd testing protocol in order to identify and eliminate all PI 
cattle.9,11  Despite a number of reports in the literature that associates BVDV with health and 
production loss,1-4,23-25 a moderate body of literature reports no adverse effects among cattle 
exposed to PI animals in both the cow-calf and feedlot sectors of the beef industry.26-28  
Additionally, the herd prevalence of PI cattle among cow-calf herd in the United States (U.S.) 
has previously been shown to be ≤ 10% indicating that the majority of beef herds do not possess 
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PI cattle.1,29,30  Therefore, given the large variation in clinical outcomes upon exposure to PI 
cattle and very few herds within the U.S. are BVDV positive, the economic viability of whole-
herd testing programs has been questioned.   
Given that numerous European countries have instituted national BVDV eradication 
programs within the last two decades,31-34 the economic justification for implementing a 
nationwide BVDV eradication campaign in the United States (U.S.) among different sectors of 
the beef industry has not been evaluated.  In addition, herd size and herd prevalence (or the 
probability that a given herd is BVDV positive) may impact the value of whole herd testing 
protocols.  Lastly, due to inherent variation in the cost and accuracy of currently offered tests, the 
value of individual BVDV testing strategies (i.e. one time tests and two-test combinations) may 
be impacted by herd size and herd prevalence.  The objective of this study was to utilize Monte 
Carlo simulation to determine the relative value of various whole-herd BVDV testing strategies 
among different herd sizes and herd prevalences within beef cow-calf herds in the U.S.   
Materials and Methods 
Model structure 
A spreadsheet model was constructed to estimate the value of implementing various 
whole-herd BVDV testing strategies in cow-calf herds across a two year timeframe in a spring 
calving beef herd.  A Monte Carlo model was initially constructed to estimate the gross income 
in a cow-calf herd based on probability distributions of known performance variables and BVDV 
herd status.  Within each iteration of the model, gross income from the cow-calf herd was 
estimated over a two year period when either applying or not applying the testing strategy.  The 
outcome variable was the difference in income between either applying or not applying the 
testing strategy.  Potential associations with the outcome variable were evaluated with testing 
strategy, herd size, and herd prevalence. 
The value of testing for PI cattle was estimated by incorporating three commonly 
performed BVDV tests (immunohistochemistry [IHC], antigen-capture ELISA [ACE], and real-
time reverse transcriptase polymerase chain reaction [PCR]) into 12 different testing strategies 
analyzed as either a single test (3) or as two-test strategies (9) applied sequentially and 
interpreted in series (Table 6-1).  Three different herd sizes (50, 100, and 500 breeding females) 
were to represent the range in cow-calf operational sizes within the U.S.   
 78
Each BVDV testing protocol was applied at three herd prevalence values (7.7%, 19%, 
47%) selected from previous literature1,29,30 to represent a range of realistic herd prevalence.  
Likewise, these values may also represent the probability (0.077, 0.19, and 0.47) that any given 
herd is BVDV positive.  Separate simulations were performed for each testing strategy and herd 
prevalence permutation in each respective herd size.   
Baseline distributions (i.e. non-BVDV associated) for health and performance parameters 
consisting of preweaning morbidity,35 health costs of morbid cattle,36-38 preweaning 
mortality,35,39-44 weaning weight,45 and cull cow %46 were determined from available literature 
(Table 6-2).  The same modeled estimates for health and production were used in both years of 
the model to ensure that these two years were not independent of one another but were correlated 
as would be expected in a herd from one year to the next.  For example, given the distribution of 
weaning weights in Table 6-2 (and the random method sampling of Monte Carlo simulation), 
failing to correlate weaning weights in both years could presumably allow for vast (and therefore 
unlikely) differences in the average weaning weights from one year to the next regardless of 
BVDV prevalence or testing strategy.   
Market prices for weaned cattle and cull cows were based on a 10 year average (1999 – 
2009) for 249.5 kg (550 lb) steers ($110/45.4 kg, [$110/cwt]) and utility cow price ($43/45.5 kg, 
[$43/cwt]), respectively (Table 6-2).47  For weaned cattle, a price slide of $0.05/0.45 kg 
($0.05/lb) was implemented whereas all cull cows were assumed to be classified as utility grade. 
The bull:cow ratio was assumed to be 1 bull for every 20 females regardless of herd BVDV 
status.48   
The within-herd BVDV prevalence (for both calves and mature animals)1,15,49-51 was 
modeled based on estimates from prior data (Table 6-2).  For each simulation, if the herd was 
negative for BVDV, the within-herd BVDV prevalence was forced to be 0% and the year one 
calving percent was determined from the baseline distribution (Table 6-2).  Conversely, if the 
herd was deemed to be BVDV positive, the initial calving percent in year one (determined from 
the aforementioned distribution) was subsequently reduced due to PI cattle being in contact with 
pregnant cattle during the previous gestational period (Table 6-3).1-4  Therefore, the overall 
calving percent in BVDV positive herds was calculated by subtracting the modeled reduction in 
calving attributed to BVDV from the modeled baseline calving percent.  The number of open 
cows at the beginning of year one (for both BVDV positive and negative herds) was thereby 
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calculated by subtracting the number of live calves from the original herd size (i.e. 50, 100, or 
500 breeding females). Income calculated based on the performance of this herd was used  as the 
baseline for comparison to the estimated herd income after test strategy application.    
After baseline calculations, the impact of applying the selected BVDV testing strategy to 
the herd was evaluated.  In the present study, a whole-herd BVDV test was defined as testing all 
live calves, open cows and bulls, and cows from test-positive calves.9  Therefore, the model 
assumes that BVDV tests were performed on calves shortly after birth (in the spring) to remove 
PI cattle early in life thereby avoiding further exposure to the cow herd during the subsequent 
breeding season and to the remaining calf crop during the subsequent months.  
The present study evaluated 12 BVDV testing modalities that included both single and 
two-test protocols (Table 6-1).  The cost of individual BVDV tests and test set-up fees were 
modeled as probability distributions according to prices offered by numerous veterinary 
diagnostic laboratories in the U.S. (Table 6-4).  These fees reflect prices of individual tests as of 
January 1, 2010.  In regards to diagnosing PI cattle in the present study, single test protocols 
defined a PI diagnosis based on a single positive test result.  Conversely, testing modalities 
requiring two tests were applied in a sequential manner with series interpretation.  Therefore, 
only cattle testing positive on the initial test were evaluated by the second test; consequently, a 
diagnosis of being a PI animal (in a multiple test protocol) was only confirmed after both tests 
were observed to be positive.  Diagnostic sensitivity (Se) and specificity (Sp) estimates for IHC, 
ACE, and PCR were determined from distributions gleaned from available literature (Table 6-5). 
 In the field, performing diagnostic tests sequentially (and interpreting in series) is 
implemented in order to elevate diagnostic Sp thereby increasing the positive predictive value of 
the test (compared to a single test protocol).  In two-test protocols, conditional independence 
presumes that the outcome of the second test is independent of the initial test (regardless of the 
outcome on the initial test).  In reality, diagnostic tests that identify similar molecules (e.g. 
antibodies, antigen) are biologically related; therefore, when implementing a testing strategy that 
uses multiple tests to detect BVDV antigen, cattle that test positive on the initial test are more 
likely to test positive on the confirmatory test.  This lack of test independence has been 
previously described as test covariance.52,53  Therefore, despite the ability of serial interpretation 
to increase test Sp, the augmentation may not be as vast as expected when assuming that 
conditional independence resides among individual tests.  In the present model, covariance 
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estimates (positive or negative) among tests in all multiple testing programs were calculated 
from available literature and then evaluated in the model as probability distributions (Table 6-5).  
Due to the lack of available data on correlations among all test permutations evaluated in the 
present study, the aforementioned values calculated from the existing literature were 
implemented for each two-test strategy.  Positive and negative covariance values were modeled 
to influence the Se and Sp of the confirmatory test based on dependency with the initial test.      
Based on herd BVDV status (positive or negative), within herd prevalence, and test 
strategy characteristics (diagnostic Se and Sp, test covariance), the model then determined the 
number of true positive (TP), false negative (FN), false positive (FP), and true negative (TN) 
diagnoses present within each herd iteration.  Cattle of TP status (i.e. true PI animals) housed 
within positive herds were modeled with the probability of dying prior to weaning age1,54,55 and 
the magnitude of a reduced weaning weight if they live (Table 3).1,56  Therefore, the number of 
TP cattle that died prematurely was subtracted from the total number of weaned calves in both 
the testing and non-testing herds in year one.  Current recommendations suggest that test positive 
cattle should be euthanized upon receipt of diagnostic test results and the model assumed this 
occurred.9,12  The removal of TP cattle among testing herds changed herd status to BVDV 
negative.  Therefore, herds removing all TP cattle avoided detriments to susceptible cattle 
(unless FN cattle were retained; see below) associated with retaining BVDV in the herd (Tables 
6-2 and 6-3).    Therefore, the cost of the TP calf to the testing herd was comprised of not only 
the individual test cost but also the loss of the projected market price that would have been 
realized for that respective PI animal had a diagnostic protocol not been implemented and if that 
calf had lived long enough to be sold (as was observed in the non-testing herd).  Herds that did 
not test for BVDV (and therefore did not know individual animal BVDV status) did not incur the 
cost of euthanizing TP animals as they would have sold cattle of TP status that lived to weaning. 
If FN diagnoses (i.e. PI cattle falsely classified as negative) were observed, these animals 
were assumed to be retained thereby allowing continued BVDV exposure to the remaining cattle 
of the testing herd.  If FN cattle were observed, all health and production benefits for eliminating 
TP cattle (discussed above) were lost and morbidity, mortality, weaning weights, and cull cow 
percent were negatively impacted (Table 6-3) as BVDV remained in the herd (due to the 
presence of FN animals and continual BVDV exposure).  For BVDV negative herds, no cost of 
TP or FN cattle was ever realized. 
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In accordance with current recommendations for test-positive cattle, cattle determined to 
be of FP diagnoses were also euthanized.  Therefore the cost of FP cattle to the present herd was 
realized by both the test costs and the loss of income that would have been generated by that 
animal had that animal been correctly classified (i.e. TN status) and not euthanized.  However, in 
contrast to TP cattle (who were modeled with the probability of being lighter at weaning), the 
potential market value of FP cattle equaled that of healthy cattle weaned and sold by the testing 
herd.  Because they were euthanized, the number of FP cattle was then subtracted from the final 
number of weaned calves available for marketing in the testing herd only.  Herds that did not test 
for BVDV (i.e. non-testing herds) did not incur this cost. The cost attributed to cattle correctly 
determined to be of TN status was modeled as the test cost of the respective test strategy.  No 
further health or production costs to the herd were incurred by TN cattle. 
In order to fully estimate the cumulative value of implementing whole-herd testing 
strategies in year one across a two-year timeframe, it was assumed that no BVDV testing would 
take place and that no replacement animals were procured in year two.  Therefore, the number of 
breeding females for both the testing and non-testing herds entering year two was determined by 
subtracting cows found to be test positive (i.e. either TP or FP status which was a rare event and 
only determined in testing herds) and cows that were culled at the end of year one from the 
original number of breeding females that entered year one.  The BVDV herd status in year two 
for herds instituting a testing strategy in year one (i.e. testing herds) was based upon the presence 
or absence of FN cattle remaining in the herd during year one.  Conversely, the BVDV status of 
the non-testing herd in year two was forced to be the same as in year one as it was assumed that 
BVDV was carried over into year two’s calf crop.  The baseline calving % for both testing and 
non-testing herds in year two was forced to equal that of year one.  However, as was assumed in 
year one, herds found to be BVDV positive in year two (both testing and non-testing herds) 
suffered the same magnitude of reproduction loss that was modeled in year one due to the 
presence of BVDV (Table 6-3).  The magnitude of reproduction loss in year two also was forced 
to equal that of year one.  The within-herd prevalence for positive herds in year two was forced 
to be equal to or less than that of year one (Table 6-2).  If herd BVDV status was positive, the 
respective herd observed impacts in morbidity, mortality, weaning weights, and increased cull 
cow risk as in year one. 
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Sensitivity Analysis 
The sensitivity of the outcome variable was analyzed for each testing strategy — herd 
prevalence — herd size permutation.  Reported values convey the percentage of variance 
contributed by each respective input value to the outcome variable (i.e. the cumulative value of 
testing for BVDV across a two year timeframe).  For each of the testing strategies, five largest 
contributors of variance were reported for each of the BVDV herd prevalence-herd size 
permutations. 
Application of the Model 
The model was conducted with a commercial Monte Carlo simulation programa,an add-in 
for a commercial software packageb.  Each simulation included 10,000 iterations using a fixed 
random number seed.  Descriptive statistics (mean and standard deviation) and 95% prediction 
intervals were produced by the simulation programa.  Iterations were captured from all models 
and combined into three independent data sets (by herd size) and evaluated with mixed models 
by a commercial statistical programc.  In all models, the cumulative value of the testing strategy 
across both years one and two was the response variable.  Fixed effects included herd BVDV 
status (positive or negative), BVDV testing strategy, herd BVDV prevalence, and the testing 
strategy by herd prevalence interaction.  An alpha level of 0.05 was implemented for all 
analyses. 
Results 
 Application of the model 
In the present study, BVDV test strategy, herd prevalence, and the test strategy by herd 
prevalence interaction was found to be significantly associated (P<0.05) with the cumulative 
value of testing for BVDV across a two year timeframe in U.S. cow-calf herds.  Across all 
testing strategies and herd BVDV prevalences, the model-adjusted value of testing for BVDV for 
BVDV positive herds (among all herd sizes) was always a profitable venture and was 
significantly greater (P<0.05) when compared to herds of BVDV negative status (Table 6-6).  
Across all testing modalities, significant differences (P<0.05) were observed between all three 
herd prevalences within each respective herd size (Table 6-6).  Testing for BVDV when the herd 
prevalence was elevated (47%) was always an economically valid practice by the second year in 
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each of the three herd sizes (regardless of test strategy) (Table 6-6).  Conversely, lower herd 
prevalences (19% and 7.7%) failed to observe a profitable outcome in each of the three herd 
sizes regardless of testing strategy (Table 6-6). 
The testing strategy by herd prevalence effect was significantly associated (P<0.05) with 
the cumulative value of implementing BVDV testing strategies across a two year timeframe for 
each respective herd size. These model-adjusted estimates are displayed in Table 6-7.  Across all 
three herd sizes, Test 2 (initial test: IHC, confirmatory test:  IHC) was observed to be the 
superior testing strategy (or did not statistically differ from Test 6 [initial test: PCR, confirmatory 
test: PCR] or Test 8 [initial test: ACE, confirmatory test:  IHC]) in all but the lowest prevalence 
in the 50 head herd.  In this case, Test 8 was the superior test (despite all cumulative estimates at 
the end of year two being of negative value in this respective scenario).  Conversely, Test 3 
(initial test:  ACE, confirmatory test:  none) displayed either the poorest or tied as the poorest 
performer at each herd prevalence within each respective herd size (Table 6-7).  The remaining 
test strategies alternated ranks depending upon herd size and herd prevalence (Table 6-7).  
Among all herd sizes, the majority of two-test protocols displayed a positive economic outcome 
when the herd prevalence reached the 47% level.  However, in all scenarios, single-test strategies 
(Tests 1, 3, and 5) failed to be observed as the superior testing modality; however, in all three 
herd sizes, testing strategies 1 and 5 did display positive economic outcomes when herd 
prevalences reached the 47% level (Table 6-7). 
 The cumulative value of implementing each respective testing strategy for each of the 
three modeled herd BVDV prevalences in a 100 head beef cow herd is graphically displayed in 
Figure 1.  Although not statistically evaluated across herd sizes, instituting whole-herd BVDV 
testing strategies when herd prevalence (or the likelihood of a herd being BVDV positive) is low 
(19% and 7.7% in this model) is rarely an economically beneficial endeavor.  Graphical 
observations for herd sizes of 50 and 500 cows displayed similar interpretation. 
Sensitivity Analysis 
Sensitivity analyses were performed for all testing strategies for each herd prevalence 
among all three herd sizes.  For illustrative purposes, sensitivity analyses for the most favorable 
(Test 2 [initial test: IHC, confirmatory test:  IHC]) and the poorest testing strategy (Test 3 [initial 
test:  ACE, confirmatory test:  none]) are displayed in Table 6-8.  The top five contributors to the 
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variance of the cumulative value of testing for BVDV over a two year period are listed.  For Test 
2 (initial test: IHC, confirmatory test:  IHC), cost of the initial test explained a vast majority of 
the variance across all three herd prevalences at each of the three herd sizes (Table 6-8).  In Test 
3 (initial test:  ACE, confirmatory test:  none), specificity of the test was the major contributor of 
variance for both all herd prevalence levels across all three herd sizes (Table 6-8).   
Discussion 
The findings in the present study indicate that across all three evaluated herd sizes (50, 
100, and 500 breeding females), BVDV test strategy, herd prevalence, and the test strategy by 
herd prevalence interaction are significantly associated (P<0.05) with the cumulative value of 
testing for BVDV across a two year timeframe in U.S. cow-calf herds.  These data are relevant as 
they convey the extreme necessity of critically evaluating the economic constraints of 
considering a national BVDV eradication program as well as instituting a whole-herd BVDV 
testing protocol within individual cow-calf herds.   
Overall, these data suggest that a positive economic outcome among U.S. cow-calf herds 
implementing a whole herd BVDV eradication campaign will only be realized when herd 
prevalence (i.e. the proportion of herds housing ≥ 1 PI animal) is relatively high (47% in this 
study).  This issue is highly significant from a regulatory aspect given the concern of whether or 
not a national BVDV eradication program is necessary in the U.S.  In Europe, numerous 
countries have initiated BVDV eradication programs.  Herd prevalences among dairy herds in 
the countries of Denmark, Sweden, Norway, and Germany have been shown to vary between 25-
50%.32-34,57,58  In comparison, the BVDV herd prevalence in the U.S. has repeatedly been shown 
to be ≤ 10% indicating that only a very small number of herds would ever benefit from a whole 
herd testing program.1,29,30  Consequently, due to the low nationwide herd BVDV prevalence, our 
data suggests that a national BVDV eradication program in the U.S. is not economically justified 
at the individual producer level.   
Shifting the focus from the national herd population to individual herds, the term “herd 
prevalence” can be substituted with the probability of an individual herd being BVDV positive.  
Practicing veterinarians work with individual herds and generally have a thorough understanding 
of that production system; therefore, the decision to recommend a whole herd testing strategy is 
based on the probability that the respective herd possesses PI cattle.  Although the data in the 
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present study suggests that herds deemed to be BVDV positive demonstrate a positive economic 
outcome by the second year after a testing protocol is implemented (Table 6-6), in reality the true 
BVDV status of a herd is typically unknown (unless a whole herd test is performed).  Therefore, 
in lieu of a whole herd test, veterinarians assess the probability that individual herds are BVDV 
positive or negative based upon clinical and reproductive history, animal procurement practices, 
and diagnostic test results on dead cattle.  Although this process is a standard method of clinical 
practice, previous research observed that only 19% of herds suspected of harboring PI cattle by 
the herd veterinarians were truly positive for PI cattle upon testing.30  However, prior research 
has displayed that the likelihood of introducing BVDV to the resident herd across a 10 year 
timeframe when pregnant heifers were imported was 47% if the calves were not BVDV tested 
upon parturition.59  Therefore, in addition to the national herd prevalence value of 7.7%, these 
two values (19% and 47%) constitute the herd prevalences evaluated in the present study and 
thereby also represent the likelihood that any given herd is BVDV positive.   
Based on the findings in the present study, accurate discernment of probable herd BVDV 
status is imperative to avoid large financial losses attributed to the respective whole herd test 
(Table 6-6).  For example, in herd sizes of 50, 100, and 500 cows, instituting a whole herd 
BVDV test based on the veterinarian’s belief that the probability of the herd being positive is 
0.47 when in reality the true probability is 0.19 costs the herd ~ $400, $800, and $4000, 
respectively, on average (Table 6-6).  Therefore, practicing veterinarians must have a clear 
understanding of the risk of being BVDV positive in each respective herd and thereby accurately 
categorize the probability of being BVDV positive in order to minimize negative economic 
outcomes. 
Several factors other than the optimal economic value comprise the decision of which 
BVDV testing modality should be implemented.10,11  Testing in series does require that a second 
test be performed on cattle that test positive on the initial test.  Veterinarians may subsequently 
find that a two-test strategy may be met with some opposition by producers thereby reducing the 
compliance of performing the second test.  Although economic benefit may not be maximized, 
the data in the current study suggests that numerous testing strategies (including one-time test 
strategies Tests 1 [initial test:  IHC, confirmatory test:  none] and 5 [initial test:  PCR, 
confirmatory test:  none]) are financially sensible at high herd BVDV prevalences in each of the 
three herd sizes (Table 6-7).  Therefore, as long as herd prevalence is high or the probability of a 
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herd being BVDV positive is high, veterinarians can tailor their test strategy to meet the practical 
and logistical limits of their staff, their clientele, and their laboratory of choice.  However, given 
the above findings, if Test 3 (initial test:  ACE, confirmatory test:  none) is implemented, we 
advise against euthanizing test positive cattle to avoid the financial loss incurred from false 
positive diagnoses.  In these cases, isolating and feeding test positive cattle until market weight is 
attained can be a viable option; however, this can create some logistical and biosecurity concerns 
to the producer if true PI cattle are retained on the farm.  In addition, if test-positive cattle are 
truly PI with BVDV, they may not perform as well as FP cattle and are at a greater risk of dying 
before they reach market weight.1,54-56 
As stated above, numerous clinical indications will dictate if a whole herd test is 
necessary and economically justifiable.  In these cases, it is essential to know which testing 
strategies will provide the most value to the producer.  In the present study, IHC on skin tissue 
followed by a confirmatory IHC test on initial positives (Test 2) was consistently the superior (or 
one of the superior) testing strategies across herd prevalence and herd size.  Therefore, not only 
is testing for BVDV economically justified at elevated herd prevalences, implementation of Test 
2 will maximize the financial return to the producer at the herd sizes evaluated in the current 
study.  The sensitivity analysis for this testing strategy indicates that the testing cost is the 
driving factor contributing to the variance in cumulative value.  However, across all herd sizes, 
as herd prevalence increased, the cost of the test declined in rank of variation contribution.  This 
is likely attributed to an elevation in the value of testing for BVDV due to a greater likelihood of 
detecting PI cattle at high herd prevalences thereby reducing the economic impacts attributed to 
test cost. 
Conversely, a onetime ACE test on skin tissue (Test 3) performed poorly (Table 6-7) at 
each herd prevalence level within each herd size.  The sensitivity analysis performed for this test 
indicates that diagnostic Sp of Test 3 is a major contributor for this result among all three herd 
prevalences and herd sizes evaluated.  While previous estimates comprising to the distribution of 
diagnostic Sp used in the current study may appear adequate, in low prevalence scenarios the 
probability of a test positive specimen being of FP status is typically greater than that of TP.  In 
test and cull programs, the sensitivity values indicate that false-positive diagnoses (especially at 
low herd prevalences) greatly impacts the value of the testing method to the producer.  Only 
when herd BVDV prevalence levels reached 47% did diagnostic Sp become relatively 
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comparable to other variance contributors.  This is likely attributed to the fact that at high herd 
prevalences, the probability that test positive cattle are truly diseased (i.e. positive predictive 
values) is elevated.53  Conversely, diagnostic Sp for Test 2 did not contribute to the variance for 
this test strategy; which is likely attributed to the serial testing method implemented to reduce the 
likelihood of false positive diagnoses.53  Therefore, in populations in which disease prevalence is 
low, maximizing the diagnostic Sp of the respective test protocol is necessary to minimize false-
positive diagnoses.   This finding is important as veterinary diagnostic laboratories are often 
asked to interpret test outcomes for both practicing veterinarians and their clientele.  However, 
based on a previous survey of 26 fully accredited veterinary diagnostic laboratories in the U.S., 
only 55% indicated that they provide BVDV management information to veterinarians or 
producers who submit samples.60  Additionally, of those diagnostic laboratories stating they do 
provide counseling, only 61% recommended confirmatory testing on cattle with positive test 
results.60    The findings in the present study suggest that regardless of herd size, diagnostic test 
Sp should be a major concern to practicing veterinarians and diagnostic laboratories.  Therefore, 
two-test strategies are optimal (although not exclusive; see below) to reduce the risk of FP 
diagnoses especially at low herd prevalences. 
Despite the data in the present study, all findings were generated by model simulation 
and therefore are dependent upon the quality of the model and the information comprising model 
input and not upon empirical data.  Although the present model was designed to incorporate the 
main production parameters among beef cow-calf herds in the U.S., we acknowledge that many 
cow-calf production systems don’t follow the same model which may impact the value of BVDV 
testing.  Therefore, it may be difficult to extrapolate our data to herds that employ other 
management practices (e.g. fall-calving herds).  To our knowledge, the distributions in the 
present model reflect the available data within the veterinary literature.  Where data was sparse, 
distributions were widened to accommodate that lack of knowledge.  Therefore, as more data is 
accumulated, model distributions (and subsequently the outcome variable) may become more 
precise. 
In summary, across all 12 testing strategies, our findings suggest that herd BVDV 
prevalence dictates the economic viability of implementing BVDV testing programs in 50, 100 
and 500 head herd sizes.  These findings provide evidence that when the predictive probability of 
a herd being BVDV positive is relatively low (0.077 and 0.19), recommending whole-herd 
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testing for BVDV is not financially beneficial.  Therefore, given that the herd BVDV prevalence 
of the United States is ≤ 10%, a national BVDV eradication program is not economically 
justified at the producer-level.  Conversely, private practitioners are urged to reserve the 
implementation of whole herd testing regimens for herds that are highly probable of possessing 
BVDV.  If a whole-herd test is performed and the probability of BVDV is high, our data indicate 
that the value of testing can be maximized in most cases by implementing a testing strategy 
consisting of IHC on skin tissue as the initial test followed by a second IHC test on individuals 
that test positive on the first test.  A onetime ACE test on skin tissue (Test 3) performed the 
worst of all 12 testing strategies.  The sensitivity analysis for Test 3 indicated that diagnostic Sp 
(or probability of a FP diagnoses) was the major variance contributor to the value of the testing 
strategy.  This suggests that financial losses were attributed to euthanizing FP cattle in herds that 
implemented that respective test strategy.  The data presented in the present study provides 
evidence that the value of whole-herd BVDV testing among cow-calf herds in the U.S. must be 
critically analyzed prior to implementation. 
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Sources and Manufacturers  
a.  Oracle® Crystal Ball, Fusion edition, release 11.1.1.3.00 (Oracle Corp., Redwood Shores, CA, 
USA) 
b.  Microsoft® Excel 2007 (© 1985-2007 Microsoft Corp., Redmond, WA, USA) 
c.  Proc Mixed, SAS [Version 9.1], Cary, N.C. 
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Table 6.1:  BVDV testing modalities evaluated in the present study. 
Test  Initial Test  Confirmatory Test 
1 IHC none 
2 IHC IHC 
3 ACE none 
4 ACE ACE 
5 PCR none 
6 PCR PCR 
7 IHC ACE 
8 ACE IHC 
9 PCR ACE 
10 PCR IHC 
11 IHC PCR 
12 ACE PCR 
 
 91
Table 6.2:  Input distributions for numerous baseline herd-level factors used in the model. 
Parameter Description  Distribution  Truncate values  Source 
Bernoulli (Yes/No)  0 ‐ 1  Wittum et al 2001 
(0.077/0.923) 
(0.19/0.81) 
(0.47/0.53) 
  Waldner et al 2008 
USDA‐APHIS Info Sheet 2009 
Smith et al 2009 
Herd BVDV Prevalence 
    Unpublished data 
Lognormal  0.12% ‐ 30.0%  Cornish et al 2005 
(0, 5.05%, 8.7%)    Waldner et al 2008 
Within Herd PI prevalence           
(Calves)* 
    Unpublished data 
Log‐Normal  0% ‐ 30%  White et al 2007 
(0, 0.04%, 0.05%)    Smith et al 2008 
Within Herd PI prevalence            
(Mature Cattle) 
    Gnad et al 2005 
Triangular  85.5% ‐ 95.5%  SPA‐2000 (ISU‐IRM) 
(85.5%, 91%, 95.5%)    SPA‐2001 (Herds from IA, IL, and MI) 
    SPA‐2002 (Herds from IA and IL) 
    SPA‐2003 (Herds from IA, IL, KY, MI) 
    SPA‐2000 (ND/SD herds) 
Calving % 
    SPA‐2005 (Herds from IA and IL) 
Pre‐weaning Morbidity  Triangular  0% ‐ 5.32%  NAHMS Beef Part II:  1997 Beef Cow‐Calf Health 
  (0%, 3.8%, 5.32%)    & Health Management Practices 
Triangular  $5.00 ‐ $20.00  Salman, et al 1991a 
($5.00, $12.00,$20.00)    Salman, et al 1991b 
Health costs of morbid cattle 
(costs per hd) 
    Hird, et al 1991 
Triangular  2.8% ‐ 4.9%  SPA‐2000 (ISU‐IRM) 
(2.8%, 3.5%, 4.9%)    SPA‐2001 (Herds from IA, IL, and MI) 
    SPA‐2002 (Herds from IA and IL) 
    SPA‐2003 (Herds from IA, IL, KY, MI) 
    SPA‐2000 (ND/SD herds) 
    SPA‐2005 (Herds from IA and IL) 
Pre‐weaning Mortality                
(birth to weaning) 
    NAHMS Beef Part II:  1997 Beef Cow‐Calf Health & 
Health Management Practices 
Weaning weight (lbs)  Normal  300 ‐ 660  USDA Beef 2007‐08 Part I: Reference of Beef Cow‐
calf 
  (530, 92)    Management 
      Practices in the United States, 2007–08 
Cull Cow %  Triangular  10% ‐ 15%  USDA Beef 1997 Part III: Reference of 
  (10%, 12%, 15%)    1997 Beef Cow‐Calf Production 
      Management and Disease Control 
Cull Cow market price  Normal ($0.43, $0.04)  $0.30 ‐ $0.56  Iowa State University Extension‐Ag Decision Maker 
      Utility Cow Price 
      1999‐2009 
*Within‐herd BVDV prevalence was only relevant if herd BVDV status was found to be positive.
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 Table 6.3:  Input distributions describing the additional health effects inflicted by BVDV. 
Parameter Description  Distribution  Truncate values  Source 
Reduction in Calving % due to BVDV 
(conception loss, abortion, stillbirths) 
Triangular           
(0%, 2%, 30%) 
0% ‐ 30%  Waldner et al, 2008    
Kelling et al, 1990         
Taylor et al, 1997             
Van Campen et al 2000 
Additional pre‐weaning morbidity        
(due to retainment of PI cattle in herd) 
Triangular           
(0%, 5%, 10%) 
0% ‐ 10%  Kelling et al 1990      
Waldner et al 2008 
Additional pre‐weaning mortality         
(due to retainment of PI cattle in herd) 
Triangular           
(0%, 1%, 10%) 
0% ‐ 10%  Waldner et al, 2008    
Kelling et al, 1990         
Taylor et al, 1997             
Van Campen et al 2000 
Assumed reduction in weaning weight 
(due to retainment of PI cattle in herd) 
(lbs) 
Triangular           
(12.1, 28.6, 44.7) 
12.1 ‐ 44.7  Waldner et al 2008 
Probability of PI cattle surviving until 
weaning 
Triangular           
(0, 0.5, 1.0) 
0 ‐ 1  Houe 1992                   
Houe 1993                  
Waldner et al 2008 
Assumed reduction in weaning weight of 
PI calf                                   
(if calf lived to weaning)                   
(lbs) 
Triangular           
(68, 162, 255) 
68 ‐ 180  Waldner et al 2008      
Taylor et al, 1997 
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Table 6.4:  Input distributions regarding laboratory fees for individual BVDV diagnostic 
tests. 
Parameter Description  Test  Distribution  Truncate values  Source 
Kansas State University 
Iowa State University 
South Dakota State University 
Test Setup Fee ($)         
(initial and confirmatory 
tests) 
All testing 
modalities 
Triangular          
($0, $8, $13) 
$0 ‐$13 
Colorado State University 
Kansas State University 
Iowa State University 
South Dakota State University 
IHC 
Triangular          
($4.00, $4.33, 
$5.50) 
$4.00 ‐ $5.50 
Colorado State University 
Kansas State University 
Iowa State University 
South Dakota State University 
ACE 
Triangular          
($4.50, $6.00, 
$9.00) 
$4.50 ‐ $9.00 
Colorado State University 
Test Cost ($) 
Real‐time 
PCR 
Triangular          
($5.70, $6.00, 
$6.30) 
$5.70 ‐ $6.30  Kansas State University 
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Table 6.5:  Input distributions for diagnostic tests listed in Table 3. 
Parameter Description  Test  Distribution  Truncate values  Source 
Thur et al 1996 
Njaa et al 2000 
Cornish et al 2005 
Fulton et al 2006 
Grooms et al 2002 
IHC 
Triangular              
(97.6%, 99.6%, 100%) 
97.6% ‐ 100% 
Brodersen et al 2004 
Cornish et al 2005 
Fulton et al 2006 
Hilbe et al 2007a 
Kuhne et al 2005 
ACE 
Triangular              
(98%, 100%, 100%) 
98% ‐ 100% 
Edmondson et al 2007 
Test Sensitivity 
Real‐time 
PCR 
Triangular              
(99%, 100%, 100%) 
99% ‐ 100%  Reinauer et al 2007 
Cornish et al 2005 
Fulton et al 2006 
Hilbe et al 2007a 
IHC 
Triangular              
(98.8%, 99.6%, 100%) 
98.8% ‐ 100% 
Grooms et al 2002 
Cornish et al 2005 
Fulton et al 2006 
Hilbe et al 2007a 
Hilbe et al 2007b 
Kuhne et al 2005 
ACE 
Triangular              
(97.7%, 99.3%, 100%) 
97.7% ‐ 100% 
Edmondson et al 2007 
Test Specificity 
Real‐time 
PCR 
Triangular              
(99%, 100%, 100%) 
99% ‐ 100%  Reinauer et al 2007 
Cornish et al 2005 
Fulton et al 2006 
Hilbe et al 2007a 
Grooms et al 2002 
Test Covariance 
(positive) 
All testing 
modalities 
Triangular              
(0, 0.006, 0.045) 
0 ‐ 0.045 
Hill et al 2007 
Cornish et al 2005 
Fulton et al 2006 
Hilbe et al 2007a 
Grooms et al 2002 
Test Covariance 
(negative) 
All testing 
modalities 
Triangular              
(0, 0.019, 0.045) 
0 ‐ 0.045 
Hill et al 2007 
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Table 6.6:  Model-adjusted1 means (and 95% confidence intervals) of the value of 
performing whole herd BVDV tests in U.S. cow-calf herds at herd sizes of 50, 100, and 500 
head.  For both independent factors (individual herd BVDV status and herd BVDV 
prevalence), superscripts within each column denote statistical differences at the 0.05 level. 
      Herd Size 
      50  100  500 
Pos  $1,091.18
a
  ($1,084.68, $1,097.67)  $2,213.57
a 
    ($2,201.82, $2,225.32)  $9,178.33
a 
      ($9,178.33, $9,310.75) Individual 
Herd BVDV 
Status  Neg  ‐$377.63
b
   (‐$377.63, ‐$370.21)  ‐$852.64
b      (‐$860.35, ‐$846.92)  ‐$4,533.20b     (‐$4,371.11, ‐$4,495.29) 
 
47%  $316.07
a      ( $309.59, $322.56)  $593.69a        ( $581.62, $605.77)  $2,044.89a       ( $2,151.07, $2,595.25) 
19%  ‐$96.04
b
      (‐$102.53, ‐$89.56)  ‐$262.89
b
      (‐$274.97, ‐$250.81)  ‐$2,034.76
b
     (‐$2,034.76, ‐$1,906.54) 
Herd BVDV 
Prevalence 
7.7%  ‐$260.54
c     (‐$267.02, ‐$254.05)  ‐$626.78c       (‐$638.86, ‐$614.70)  ‐$3,533.70c       (‐$3,533.70, ‐$3,405.48) 
 
1 From mixed models accounting for herd BVDV status and herd BVDV prevalence as fixed 
effects.  Only the results of the effect of interest (value of performing whole-herd BVDV testing 
strategies) are reported. 
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Table 6.7:  Model-adjusted1 means for BVDV testing strategy by herd prevalence 
interaction within herd sizes of 50, 100, and 500 head.  Superscripts within each column 
denote statistical differences at the 0.05 level. 
 
Herd Size = 50  Herd Size = 100  Herd Size = 500 
Test  7.7%  19%  47%  7.7%  19%  47%  7.7%  19%  47% 
1  ‐$179.53
c,d
  $37.75
b
  $459.03
c
  ‐$595.82
d
  ‐$105.50
d
  $776.73
d
  ‐$3261.06
e
  ‐$1667.34
d,e,f
  $2373.15
c
 
2  ‐$120.82
b
  $90.56
a
  $658.30
a
  ‐$243.95
a
  $184.40
a
  $1282.02
a
  ‐$1446.95
a
  $116.67
a
  $4964.69
a
 
3  ‐$498.38
f
  ‐$388.57
g
  ‐$107.77
i
  ‐$1067.41
e
  ‐$840.55
g
  ‐$282.60
h
  ‐$5684.86
f
  ‐$4777.30
i
  ‐$1955.80
g
 
4  ‐$484.09
f
  ‐$301.58
f
  $143.45
g
  ‐$1045.09
e
  ‐$677.09
f
  $205.84
f
  ‐5603.782
f
  ‐$4017.16
h
  ‐$87.11
e
 
5  ‐$198.89
d
  ‐$44.30
d,e
  $406.72
d
  ‐$501.39
c
  ‐$134.69
d
  $743.67
d
  ‐$2900.77
d
  ‐$1050.18
c
  $3588.99
b
 
6  ‐$202.48
d
  ‐$6.30
c
  $542.19
b
  ‐$414.07
b
  $18.30
c
  $1061.33
b
  ‐$2093.85
c
  $56.00
a
  $5155.07
a
 
7  ‐$174.28
c,d
  ‐$10.95
c
  $349.01
e
  ‐$549.98
c,d
  ‐$234.21
e
  $563.74
e
  ‐$3297.32
e
  ‐$1988.23
g
  $1237.38
d
 
8  ‐$58.58
a
  $57.83
b
  $443.97
c
  ‐$292.66
a
  $79.15
b
  $912.85
c
  ‐$1585.53
a,b
  ‐$525.91
b
  $3463.03
b
 
9  ‐$242.92
e
  ‐$73.88
e
  $312.29
f
  ‐$585.68
d
  ‐$252.80
e
  $560.95
e
  ‐$3241.53
e
  ‐$1654.88
d,e,f
  $2406.56
c
 
10  ‐$249.49
e
  ‐$65.76
e
  $327.23
e,f
  ‐$599.14
d
  ‐$261.81
e
  564.98
e
  ‐$3280.52
e
  ‐$1811.21
e,f,g
  $2530.38
c
 
11  ‐$162.98
c
  ‐$28.91
c,d
  $390.82
d
  ‐$577.83
d
  ‐$238.87
e
  $591.10
e
  ‐$3441.33
e
  ‐$2111.94
g
  $1305.67
d
 
12  ‐$495.88
f
  ‐$328.64
f
  $93.74
h
  ‐$1048.30
e
  ‐$690.99
f
  $143.69
g
  ‐$5797.50
f
  ‐$4216.31
h
  ‐$443.33
f
 
 
1 From mixed models accounting for test strategy, herd BVDV prevalence, and the test strategy 
by herd BVDV prevalence as fixed effects.  Only the results of the effect of interest (value of 
performing whole-herd BVDV testing strategies) are reported. 
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Figure 6.1:  Graphical display of the value of implementing whole-herd BVDV tests for 
each of the 12 BVDV testing strategies in a 100 cow beef herd at each of the three BVDV 
herd prevalences evaluated in the present study.  Error bars denote 95% confidence 
intervals. 
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Table 6.8:  Sensitivity analysis for Test 2 (initial test:  IHC, confirmatory test:  IHC) and 
Test 3 (initial test:  ACE, confirmatory test: none) at each respective herd size and herd 
BVDV prevalence.  Within each column, the top five contributors to variance are 
displayed.  The values reflect the individual percentage of variation of the outcome variable 
(cumulative value of testing for BVDV across a two year timeframe). 
  Herd Size = 50  Herd Size = 100  Herd Size = 500 
Test  Variable  7.70%  19%  47%  7.70%  19%  47%  7.70%  19%  47% 
Cost of initial 
Test 
‐55.2%  ‐53.1%  ‐23.6%  ‐56.4%  ‐53.6%  ‐26.1%  ‐55.8%  ‐53.2%  ‐27.7% 
Preweaning 
Morbidity 
‐31.2%  ‐30.3%  ‐16.1%  ‐29.6%  ‐29.5%  ‐12.3%  ‐30.4%  ‐29.9%  ‐13.3% 
Health Costs of 
Morbid cattle 
‐13.1%  ‐13.2%  ‐5.8%  ‐13.4%  ‐13.6%  ‐‐  ‐12.9%  ‐13.4%  ‐7.6% 
Pre‐weaning 
mortality 
‐0.1%  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐ 
Additional 
preweaning 
mortality due to 
BVDV 
0.2%  1.3%  29.2%  0.1%  1.4%  25.8%  0.2%  0.9%  17.0% 
Weaning Weight  ‐‐  0.9%  13.4%  0.1%  0.5%  15.7%  ‐‐  ‐‐  12.5% 
Cull Cow Market 
Value 
‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐6.7%  ‐‐  ‐‐  ‐‐ 
2 
Within‐herd 
BVDV prevalence 
‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐0.1%  ‐0.9%  ‐11.9% 
Specificity of 
initial test 
69.4%  69.1%  28.7%  60.6%  59.1%  26.9%  86.5%  83.9%  34.2% 
Cost of initial 
Test 
‐27.7%  ‐22.5%  ‐9.1%  ‐28.6%  ‐26.3%  ‐7.9%  ‐8.2%  ‐7.5%  ‐‐ 
Additional 
preweaning 
mortality due to 
BVDV 
0.3%  3.4%  21.9%  0.5%  3.6%  26.7%  0.3%  1.7%  20.1% 
Reduction in 
Calving % due to 
BVDV 
0.3%  1.0%  ‐‐  ‐‐  ‐‐  6.1%  ‐‐  ‐‐  4.8% 
Weaning Weight  ‐1.3%  ‐‐  ‐‐  ‐5.6%  ‐5.4%  ‐‐  ‐4.4%  ‐2.2%  ‐‐ 
3 
Within herd 
BVDV prevalence 
in Year 1 
‐‐  ‐1.8%  ‐14.6%  ‐0.4%  ‐2.5%  ‐17.7  ‐0.4%  ‐2.5%  ‐22.6% 
Probability of a PI 
calf surviving 
until weaning 
‐‐  ‐‐  ‐9.5%  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐ 
Within herd 
BVDV prevalence 
in Year 2 
‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐‐  ‐7.1% 
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CHAPTER 7 - Dissertation Conclusion 
Current veterinary literature has repeatedly displayed the complexity and unpredictability 
of BVDV.  These characteristics have provided researchers the opportunity to observe a high 
degree of volatility in beef production when BVDV is present.  The sources of this variability are 
likely broad but our work has proposed that one factor may be the quantity of virus shed by 
individual PI cattle.  In addition, BVDV strain differences, the level of herd immunity, and the 
degree of stress placed on susceptible cattle (among others) likely play a role in the development 
of clinical disease among cattle exposed to BVDV.  Given that PI cattle are the likely reservoir 
of the virus, BVDV control programs are highly focused at identifying (and removing) PI cattle 
(diagnostic tests), elevating herd immunity (vaccines), and preventing introduction of BVDV to 
the resident cow-calf herd (biosecurity).  Given these widely adopted tools, prevention and 
control of BVDV can be effectively performed and our data would suggest that producer 
education has benefited this endeavor.  However, from a diagnostic test standpoint, our data 
infers that herd prevalence, or the probability of a herd being BVDV positive, should be 
relatively high in order to economically justify a whole-herd testing strategy.  Therefore, due to 
the low BVDV herd prevalence among U.S. beef cow-calf herds, a nationwide BVDV 
eradication program implemented within this sector of the U.S. beef industry is not a rational 
approach to reducing the risk of BVDV to beef production systems.  Alternatively, veterinarians 
should evaluate each herd for its likelihood of housing PI cattle; the decision to implement a 
diagnostic test strategy is then based on those findings.  
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